SPT - Interim / Quarterly Report 2025

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS AND INDEPENDENT AUDITORS’ REVIEW REPORT JUNE 30, 2025 AND 2024

For the convenience of readers and for information purpose only, the auditors’ report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors’ report and financial statements shall prevail.

~1~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES

JUNE 30, 2025 AND 2024 CONSOLIDATED FINANCIAL STATEMENTS AND INDEPENDENT AUDITORS’ REVIEW REPORT

Contents	Page
1. Cover Page 2. Table of Contents 3. Independent Auditors’ Review Report 4. Consolidated Balance Sheets 5. Consolidated Statements of Comprehensive Income 6. Consolidated Statements of Changes in Equity 7. Consolidated Statements of Cash Flows 8. Notes to the Consolidated Financial Statements (1) HISTORY AND ORGANISATION (2) THE DATE OF AUTHORISATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORISATION (3) APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS (4) SUMMARY OF MATERIAL ACCOUNTING POLICIES (5) CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND	1 2 ~ 3 4 ~ 6 7 ~ 8 9 10 11 ~ 12 13 ~ 54 13 13 13 ~ 14 14 ~ 16 16

Contents

Page

1. Cover Page
2. Table of Contents
3. Independent Auditors’ Review Report
4. Consolidated Balance Sheets
5. Consolidated Statements of Comprehensive Income
6. Consolidated Statements of Changes in Equity
7. Consolidated Statements of Cash Flows
8. Notes to the Consolidated Financial Statements
(1)
HISTORY AND ORGANISATION
(2)
THE DATE OF AUTHORISATION FOR ISSUANCE OF THE
CONSOLIDATED FINANCIAL STATEMENTS AND
PROCEDURES FOR AUTHORISATION
(3)
APPLICATION OF NEW STANDARDS, AMENDMENTS AND
INTERPRETATIONS
(4)
SUMMARY OF MATERIAL ACCOUNTING POLICIES
(5)
CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND

1
2 ~ 3
4 ~ 6
7 ~ 8
9
10
11 ~ 12
13 ~ 54
13
13
13 ~ 14
14 ~ 16
16

~2~

Contents Page

	KEY SOURCES OF ASSUMPTION UNCERTAINTY
(6)	DETAILS OF SIGNIFICANT ACCOUNTS	17 ~ 41
(7)	RELATED PARTY TRANSACTIONS	41 ~ 42
(8)	PLEDGED ASSETS	43
(9)	SIGNIFICANT CONTINGENT LIABILITIES AND	43
	UNRECOGNISED CONTRACT COMMITMENTS
(10)	SIGNIFICANT DISASTER LOSS	43
(11)	SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE	43
(12)	OTHERS	43 ~ 52
(13)	SUPPLEMENTARY DISCLOSURES	52
	A. Significant transactions information	52
	B. Information on investees	52
	C. Information on investments in Mainland China	52
(14)	SEGMENT INFORMATION	52 ~ 54

~3~

INDEPENDENT AUDITORS’ REVIEW REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of ScinoPharm Taiwan, Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of ScinoPharm Taiwan, Ltd. and subsidiaries (the “Group”) as at June 30, 2025 and 2024, and the related consolidated statements of comprehensive income for the three-month and six-month periods then ended, as well as the consolidated statements of changes in equity and of cash flows for the six-month periods then ended, and notes to the consolidated financial statements, including a summary of material accounting policies. Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” that came into effect as endorsed by the Financial Supervisory Commission. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of review

Except as explained in the following paragraph, we conducted our reviews in accordance with the Standard on Review Engagements 2410, “Review of Financial Information Performed by the Independent Auditor of the Entity” of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

~4~

Basis for qualified conclusion

The financial statements of certain insignificant consolidated subsidiaries and supplementary disclosures in Note 13 were not reviewed by independent auditors. Those statements reflect total － assets of $19,031 thousand and $27,691 thousand, both constituting % of the consolidated total － assets, and total liabilities of $1,315 thousand and $9,868 thousand, constituting % and 1% of the consolidated total liabilities as at June 30, 2025 and 2024, respectively, and total comprehensive income (loss) of ($2,164) thousand, $461 thousand, ($1,452) thousand and $1,469 thousand, constituting 2%, 1%, (7%) and 1% of the consolidated total comprehensive income for the threemonth and six-month periods then ended, respectively.

Qualified conclusion

Except for the adjustments to the consolidated financial statements, if any, as might have been determined to be necessary had the financial statements of certain insignificant subsidiaries and supplementary disclosures in Note 13 been reviewed by independent auditors as described in the Basis for qualified conclusion section above, based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as at June 30, 2025 and 2024, and its consolidated financial performance for the three-month and six-month periods then ended and its consolidated cash flows for the six-month periods then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” that came into effect as endorsed by the Financial Supervisory Commission.

~5~

Yeh, Fang-Ting

Independent Auditors

Hsu, Hui-Yu

PricewaterhouseCoopers, Taiwan Republic of China August 6, 2025

------------------------------------------------------------------------------------------------------------------------------The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors’ report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

~6~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS JUNE 30, 2025, DECEMBER 31, 2024 AND JUNE 30, 2024

(Expressed in thousands of New Taiwan dollars)

Assets	Notes	June 30, 2025 AMOUNT % `$` `3,085,943 26` `6,758` `-` `-` `-` `493,788` `4` `22,105` `-` `1,895,707 16` `151,586` `1` `5,655,887 47` `1,306,599 11` `3,490,196 29` `679,168` `6` `16,589` `-` `637,224` `5` `79,108` `1` `2,939` `-` `30,940` `-` `63,858` `1` `6,306,621 53` `$` `11,962,508 100` (Continued)	December 31, 2024 AMOUNT % `$` `4,165,987` `35` `-` `-` `29,397` `-` `604,219` `5` `20,572` `-` `1,673,007` `14` `114,908` `1` `6,608,090` `55` `70,134` `1` `3,738,889` `32` `686,635` `6` `17,130` `-` `625,260` `5` `150,890` `1` `2,367` `-` `30,940` `-` `12,403` `-` `5,334,648` `45` `$` `11,942,738` `100`	June 30, 2024	June 30, 2024
		AMOUNT `$` `3,085,943` `6,758` `-` `493,788` `22,105` `1,895,707` `151,586` `5,655,887` `1,306,599` `3,490,196` `679,168` `16,589` `637,224` `79,108` `2,939` `30,940` `63,858` `6,306,621` `$` `11,962,508` (Continued)	AMOUNT `$` `4,165,987` `-` `29,397` `604,219` `20,572` `1,673,007` `114,908` `6,608,090` `70,134` `3,738,889` `686,635` `17,130` `625,260` `150,890` `2,367` `30,940` `12,403` `5,334,648` `$` `11,942,738`	AMOUNT `$` `4,206,801` `-` `-` `478,598` `15,563` `1,815,076` `156,747` `6,672,785` `49,362` `3,754,884` `692,196` `18,330` `632,578` `142,172` `2,361` `30,940` `-` `5,322,823` `$` `11,995,608`	%
Current assets 1100 Cash and cash equivalents 1110 Financial assets at fair value through profit or loss - current 1140 Contract assets - current 1170 Accounts receivable, net 1200 Other receivables 130X Inventories 1410 Prepayments 11XX Total current assets Non-current assets 1517 Financial assets at fair value through other comprehensive income - non-current 1600 Property, plant and equipment 1755 Right-of-use assets 1780 Intangible assets 1840 Deferred income tax assets 1915 Prepayments for equipment 1920 Guarantee deposits paid 1980 Other financial assets - non- current 1990 Other non-current assets 15XX Total non-current assets 1XXX Total assets	6(1) 6(2) 6(17) 6(3) and 12 6(4) 6(5) 6(6)(8) and 7 6(7) 6(6) 6(24) 6(6) 6(1) and 8 6(6)				`35` `-` `-` `4` `-` `15` `2`
					`56`
					`1` `31` `6` `-` `5` `1` `-` `-` `-`
					`44`
					`100`

~7~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

JUNE 30, 2025, DECEMBER 31, 2024 AND JUNE 30, 2024

(Expressed in thousands of New Taiwan dollars)

					June 30, 2025				December 31, 2024	December 31, 2024			June 30, 2024
	Liabilities and Equity	Notes			AMOUNT	%			AMOUNT	%			AMOUNT	%
	Current liabilities
2100	Short-term borrowings	6(9)		`$`	`82,758`		`1`	`$`	`35,563`		`-`	`$`	`8,865`		`-`
2120	Financial liabilities at fair value	6(2)
	through profit or loss - current				`-`		`-`		`1,225`		`-`		`652`		`-`
2130	Contract liabilities - current	6(17)			`166,477`		`2`		`119,396`		`1`		`144,776`		`1`
2150	Notes payable				`20`		`-`		`1,211`		`-`		`2,034`		`-`
2170	Accounts payable				`150,765`		`1`		`80,959`		`1`		`147,324`		`1`
2200	Other payables	6(10)(15)			`592,067`		`5`		`498,191`		`4`		`611,103`		`5`
2230	Current income tax liabilities	6(24)			`43,752`		`-`		`11,499`		`-`		`39,097`		`1`
2280	Lease liabilities - current				`23,797`		`-`		`19,638`		`-`		`18,627`		`-`
21XX	Total current liabilities				`1,059,636`		`9`		`767,682`		`6`		`972,478`		`8`
	Non-current liabilities
2570	Deferred income tax liabilities	6(24)			`2,099`		`-`		`1,304`		`-`		`1,438`		`-`
2580	Lease liabilities - non-current				`616,798`		`5`		`620,342`		`5`		`624,921`		`6`
2640	Net defined benefit liabilities -	6(11)
	non-current				`11,867`		`-`		`23,614`		`1`		`23,914`		`-`
2645	Guarantee deposits received				`3,649`		`-`		`3,992`		`-`		`893`		`-`
25XX	Total non-current
	liabilities				`634,413`		`5`		`649,252`		`6`		`651,166`		`6`
2XXX	Total liabilities				`1,694,049`	`14`			`1,416,934`	`12`			`1,623,644`	`14`
	Equity attributable to owners of
	parent
	Share capital	6(12)
3110	Common stock				`7,907,392`	`66`			`7,907,392`	`66`			`7,907,392`	`66`
3200	Capital surplus	6(13)			`1,294,689`	`11`			`1,294,689`	`10`			`1,294,689`	`10`
	Retained earnings	6(15)
3310	Legal reserve				`817,709`		`7`		`783,817`		`7`		`783,817`		`6`
3320	Special reserve				`126,177`		`1`		`185,856`		`2`		`185,856`		`2`
3350	Unappropriated earnings				`309,479`		`3`		`480,227`		`4`		`356,215`		`3`
3400	Other equity interest	6(16)	`(`		`186,987 )(`		`2) (`		`126,177) (`		`1)(`		`156,005) (`		`1)`
3XXX	Total equity				`10,268,459`	`86`			`10,525,804`	`88`			`10,371,964`	`86`
	Significant contingent liabilities	9
	and unrecognised contract
	commitments
3X2X	Total liabilities and equity			`$`	`11,962,508`	`100`		`$`	`11,942,738`	`100`		`$`	`11,995,608`	`100`

The accompanying notes are an integral part of these consolidated financial statements.

~8~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME SIX MONTHS ENDED JUNE 30, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars, except for earnings per share amount)

						Three months ended June 30	Three months ended June 30	Three months ended June 30	Three months ended June 30			Six months ended June 30	Six months ended June 30	Six months ended June 30	Six months ended June 30
						2025			2024			2025			2024
	Items		Notes			AMOUNT	%	AMOUNT		%		AMOUNT	%	AMOUNT		%
4000	Operating revenue	6(17)			`$`	`747,521`	`100`	`$`	`762,359`	`100`	`$`	`1,433,886`	`100`	`$`	`1,645,585`	`100`
5000	Operating costs	6(4)(11)(22)(2
		3)		`(`		`427,985 ) (`	`57) (`		`471,596 ) (`	`62) (`		`886,354 ) (`	`62) (`		`1,001,509) (`	`61 )`
5900	Net operating margin					`319,536`	`43`		`290,763`	`38`		`547,532`	`38`		`644,076`	`39`
	Operating expenses	6(7)(11)(22)(2
		3), 7 and 12
6100	Selling expenses			`(`		`31,925 ) (`	`4) (`		`45,319 ) (`	`6) (`		`61,060 ) (`	`4) (`		`80,656) (`	`5 )`
6200	General and administrative
	expenses			`(`		`93,865 ) (`	`13) (`		`94,392 ) (`	`12) (`		`187,084 ) (`	`13) (`		`185,641) (`	`11 )`
6300	Research and development
	expenses			`(`		`113,471 ) (`	`15) (`		`79,272 ) (`	`11) (`		`180,711 ) (`	`13) (`		`154,240) (`	`10 )`
6450	Expected credit gain (loss)			`(`		`10 )`	`- (`		`634 )`	`-`		`1,814`	`- (`		`555)`	`-`
6000	Total operating expenses			`(`		`239,271 ) (`	`32) (`		`219,617 ) (`	`29) (`		`427,041 ) (`	`30) (`		`421,092) (`	`26 )`
6900	Operating profit					`80,265`	`11`		`71,146`	`9`		`120,491`	`8`		`222,984`	`13`
	Non-operating income and
	expenses
7100	Interest income	6(18)				`13,341`	`2`		`16,573`	`2`		`29,116`	`2`		`30,174`	`2`
7010	Other income	6(19)				`554`	`-`		`227`	`-`		`877`	`-`		`2,070`	`-`
7020	Other gains and losses	6(2)(8)(20)
		and	12	`(`		`45,201 ) (`	`6)`		`4,308`	`1 (`		`41,850 ) (`	`3)`		`14,127`	`1`
7050	Finance costs	6(7)(21)		`(`		`2,269 ) (`	`1) (`		`2,022 )`	`- (`		`4,400 )`	`- (`		`4,067)`	`-`
7000	Total non-operating income
	and expenses			`(`		`33,575 ) (`	`5)`		`19,086`	`3 (`		`16,257 ) (`	`1)`		`42,304`	`3`
7900	Profit before income tax					`46,690`	`6`		`90,232`	`12`		`104,234`	`7`		`265,288`	`16`
7950	Income tax expense	6(24)		`(`		`12,489 ) (`	`2) (`		`15,350 ) (`	`2) (`		`24,010 ) (`	`2) (`		`50,383) (`	`3 )`
8200	Profit for the period				`$`	`34,201`	`4`	`$`	`74,882`	`10`	`$`	`80,224`	`5`	`$`	`214,905`	`13`
	Other comprehensive income
	(loss)
	Components of other
	comprehensive income (loss)
	that will not be reclassified to
	profit or loss
8316	Unrealised gain (loss) from	6(5)(16)
	equity instruments measured
	at fair value through other
	comprehensive income			`($`		`2,582 )`	`- ($`		`3,227 ) (`	`1)`	`$`	`80,465`	`6 ($`		`20,611) (`	`1 )`
	Components of other
	comprehensive income (loss)
	that will be reclassified to
	profit or loss
8361	Financial statements	6(16)
	translation differences of
	foreign operations			`(`		`171,462 ) (`	`23)`		`12,595`	`2 (`		`141,275 ) (`	`10)`		`50,462`	`3`
8300	Total other comprehensive
	income (loss) for the period			`($`		`174,044 ) (`	`23)`	`$`	`9,368`	`1 ($`		`60,810 ) (`	`4)`	`$`	`29,851`	`2`
8500	Total comprehensive income
	(loss) for the period			`($`		`139,843 ) (`	`19)`	`$`	`84,250`	`11`	`$`	`19,414`	`1`	`$`	`244,756`	`15`
	Profit attributable to:
8610	Owners of the parent				`$`	`34,201`	`4`	`$`	`74,882`	`10`	`$`	`80,224`	`5`	`$`	`214,905`	`13`
	Comprehensive income (loss)
	attributable to:
8710	Owners of the parent			`($`		`139,843 ) (`	`19)`	`$`	`84,250`	`11`	`$`	`19,414`	`1`	`$`	`244,756`	`15`
	Earnings per share (in dollars)	6(25)
9750	Basic				`$`		`0.04`	`$`		`0.09`	`$`		`0.10`	`$`		`0.27`
9850	Diluted				`$`		`0.04`	`$`		`0.09`	`$`		`0.10`	`$`		`0.27`

The accompanying notes are an integral part of these consolidated financial statements.

~9~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY SIX MONTHS ENDED JUNE 30, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars)

Notes			Equity a	Equity a	ttributable to owners o	f the parent
	Share capital - common stock	Capital reserve			Retained Earnings		Other EquityInterest
			Legal reserve		Special reserve	Unappropriated earnings	Financial statements translation differences of foreign operations	Unrealised (losses) gains from financial assets measured at fair value through other comprehensive income
6(5)(16) 6(15) 6(5)(16) 6(15)	`$` `7,907,392` `-` `-` `-` `-` `-` `-` `$` `7,907,392` `$` `7,907,392` `-` `-` `-` `-` `-` `-` `$` `7,907,392`	`$` `1,294,689` `-` `-` `-` `-` `-` `-` `$` `1,294,689` `$` `1,294,689` `-` `-` `-` `-` `-` `-` `$` `1,294,689`	`$` `755,145` `-` `-` `-` `28,672` `-` `-` `$` `783,817` `$` `783,817` `-` `-` `-` `33,892` `-` `-` `$` `817,709`	`$` `98,176` `-` `-` `-` `-` `87,680` `-` `$` `185,856` `$` `185,856` `-` `-` `-` `-` `-` `(` `59,679 )` `$` `126,177`		`$` `494,884` `214,905` `-` `214,905` `(` `28,672 )` `(` `87,680 )` `(` `237,222 )` `$` `356,215` `$` `480,227` `80,224` `-` `80,224` `(` `33,892 )` `(` `276,759 )` `59,679` `$` `309,479`	`($` `88,156` `)` `-` `50,462` `50,462` `-` `-` `-` `($` `37,694` `)` `($` `28,638` `)` `-` `(` `141,275` `)` `(` `141,275` `)` `-` `-` `-` `($` `169,913` `)`	`($` `97,700 )` `-` `(` `20,611 )` `(` `20,611 )` `-` `-` `-` `($` `118,311 )` `($` `97,539 )` `-` `80,465` `80,465` `-` `-` `-` `($` `17,074 )`	`$` `10,364,430` `214,905` `29,851` `244,756` `-` `-` `(` `237,222` `)` `$` `10,371,964` `$` `10,525,804` `80,224` `(` `60,810` `)` `19,414` `-` `(` `276,759` `)` `-` `$` `10,268,459`

The accompanying notes are an integral part of these consolidated financial statements.

~10~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS SIX MONTHS ENDED JUNE 30, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars)

CASH FLOWS FROM OPERATING ACTIVITIES
Profit before tax
Adjustments
Adjustments to reconcile profit (loss)
(Gain) loss on valuation of financial assets and
liabilities at fair value through profit or loss
Expected credit (gain) loss

Loss on inventory market price decline

Depreciation of property, plant and equipment

Depreciation of right-of-use assets

(Gain) loss on disposal of property, plant and
equipment

Gain on reversal of impairment loss

Amortisation

Interest income

Interest expense

Changes in operating assets and liabilities
Changes in operating assets
Contract assets - current
Accounts receivable
Other receivables
Inventories
Prepayments
Changes in operating liabilities
Contract liabilities - current
Notes payable
Accounts payable
Other payables
Net defined benefit liabilities - non-current
Cash inflow generated from operations
Interest received
Interest paid
Income tax paid
Net cash flows from operating activities Six months ended June 30
Notes
2025
2024
$
104,234 $
265,288
(
7,983 )
8,956
12
(
1,814 )
555
6(4)
27,675
22,091
6(6)(22)
234,512
227,874
6(7)(22)
9,978
8,613
6(20)
(
103 )
690
6(6)(8)(20)
(
63 )
-
6(22)
10,093
4,397
6(18)
(
29,116 ) (
30,174 )
6(21)
4,400
4,067
29,397
-
112,245
309,064
187
8,095
(
244,364 ) (
328,207 )
(
35,933 ) (
50,486 )
47,081
33,809
(
1,191 )
855
69,806
46,046
(
101,631 ) (
44,681 )
(
11,747 ) (
30,600 )
215,663
456,252
27,396
31,746
(
4,361 ) (
4,072 )
(
11,941 ) (
62,597 )
226,757
421,329

(Continued)

~11~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS SIX MONTHS ENDED JUNE 30, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars)

CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of financial assets at fair value through
other comprehensive income - non-current
Cash paid for acquisition of property, plant and
equipment

Proceeds from disposal of property, plant and
equipment
Acquisition of intangible assets
Cash paid for prepayments for equipment

(Increase) decrease in guarantee deposits paid
Increase in other assets - non-current
Net cash flows used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Increase in short-term borrowings

Decrease in short-term borrowings

Repayment of the principal portion of lease
liabilities

Decrease in guarantee deposits received

Net cash flows from (used in) financing
activities
Effect of foreign exchange rate changes
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period

Cash and cash equivalents at end of period Six months ended June 30
Notes
2025
2024
($
1,156,000 ) $
-
6(26)
(
92,365 ) (
29,424 )
1,237
-
(
2,665 ) (
3,336 )
6(26)
(
71,087 ) (
102,858 )
(
708 )
32
(
1,718 )
-
(
1,323,306 ) (
135,586 )
6(27)
62,759
8,780
6(27)
(
8,712 ) (
32,863 )
6(27)
(
7,626 ) (
6,224 )
6(27)
(
140 ) (
442 )
46,281 (
30,749 )
(
29,776 )
10,283
(
1,080,044 )
265,277
6(1)
4,165,987
3,941,524
6(1)
$
3,085,943 $
4,206,801

The accompanying notes are an integral part of these consolidated financial statements.

~12~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIODS ENDED JUNE 30, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

1. HISTORY AND ORGANISATION

(1) ScinoPharm Taiwan, Ltd. (the “Company”) was incorporated as a company limited by shares under the provisions of the Company Act of the Republic of China (R.O.C.) on November 11, 1997. The Company and its subsidiaries (the “Group”) are primarily engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade and research, development, production, manufacture and sales of Active Pharmaceutical Ingredients (“API”), albumin medicines, oligonucleotide medicines, peptide medicines, injections and new small molecule drugs, as well as the provision of related consulting and technical services and international trade for the above products. In addition, the Company sells the chemical material which is reprocessed from the material recycled from the Company’s manufacturing process. For more information regarding the manufacturing and trading activities the Group are engaged in, refer to Note 4(3), “Basis of consolidation”.
(2) The common shares of the Company have been listed on the Taiwan Stock Exchange since September 2011.
(3) Uni-President Enterprises Corp., the Company’s ultimate parent company, holds 37.94% equity interest in the Company.
THE DATE OF AUTHORISATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL

STATEMENTS AND PROCEDURES FOR AUTHORISATION

These consolidated financial statements were authorised for issuance by the Board of Directors on August 6, 2025.
APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS
(1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS[®] ”) Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission (“FSC”)

New standards, interpretations and amendments endorsed by the FSC and became effective from 2025 are as follows:

Effective date by International Accounting New Standards, Interpretations and Amendments Standards Board (“IASB”) Amendments to IAS 21, ‘Lack of Exchangeability’ January 1, 2025

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

~13~

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but

not yet adopted by the Group

New standards, interpretations and amendments endorsed by the FSC effective from 2026 are as follows:

==> picture [488 x 31] intentionally omitted <==

----- Start of picture text -----

Effective date by
New Standards, Interpretations and Amendments IASB
----- End of picture text -----

New Standards,Interpretations andAmendments	Effective date by IASB
Specific provisions of Amendments to IFRS 9 and IFRS 7, ‘Amendments	January 1, 2026
to the classification and measurement of financial instruments’
Amendments to IFRS 9 and IFRS 7, ‘Contracts referencing nature-	January 1, 2026
dependent electricity’
IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendments to IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendment to IFRS 17, ‘Initial application of IFRS 17 and IFRS 9 –	January 1, 2023
comparative information’
Annual Improvements to IFRS Accounting Standards – Volume 11	January 1, 2026

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(3) IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRS Accounting Standards as endorsed by the FSC are as follows:

Accounting Standards as endorsed by the FSC are as follows:
New Standards,Interpretations andAmendments Amendments to IFRS 10 and IAS 28, ‘Sale or contribution of assets between an investor and its associate or joint venture’ IFRS 18, ‘Presentation and disclosure in financial statements’ IFRS 19, ‘Subsidiaries without public accountability: disclosures’	Effective date by IASB
	To be determined by IASB January 1, 2027 January 1, 2027

Except for the following, the above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment. IFRS 18, ‘Presentation and disclosure in financial statements’

IFRS 18, ‘Presentation and disclosure in financial statements’ replaces IAS 1. The standard introduces a defined structure of the statement of profit or loss, disclosure requirements related to managementdefined performance measures, and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes.

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

Except for the compliance statement, basis of preparation, basis of consolidation and applicable policies of the interim financial statements as set out below, the other principal accounting policies are in agreement with Note 4 of the consolidated financial statements for the year ended December 31, 2024. These policies have been consistently applied to all the periods presented, unless otherwise stated.

~14~

(1) Compliance statement

A. The consolidated financial statements of the Group have been prepared in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers”, and IAS 34, ``` Interim Financial Reporting’ that came into effect as endorsed by the FSC.
B. The consolidated financial statements should be read together with the consolidated financial statements for the year ended December 31, 2024.
(2) Basis of preparation
A. Except for the following items, these consolidated financial statements have been prepared under the historical cost convention:
- (a) Financial assets and financial liabilities (including derivative instruments) at fair value through profit or loss.
- (b) Financial assets at fair value through other comprehensive income.
- (c) Defined benefit liabilities recognised based on the net amount of pension fund assets less present value of defined benefit obligation.
B. The preparation of financial statements in conformity with International Financial Reporting Standards, International Accounting Standards, IFRIC[®] Interpretations and SIC[®] Interpretations that came into effect as endorsed by the FSC (collectively referred herein as the “IFRSs”) requires that use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.
(3) Basis of consolidation
A. Basis for preparation of consolidated financial statements:
- The basis for preparation of these consolidated financial statements is consistent with those for the preparation of consolidated financial statements for the year ended December 31, 2024.
B. Subsidiaries included in the consolidated financial statements:

Name of Name of Investors Subsidiaries ScinoPharm Taiwan, Ltd. SPT International, Ltd. ScinoPharm Taiwan, Ltd. ScinoPharm Singapore Pte Ltd.	Business Activities Professional investment Professional investment	June 30, December 31, June 30, 2025 2024 2024 100.00 100.00 100.00 100.00 100.00 100.00 Company Percentage owned by the	Note
		June 30, December 31, 2025 2024 100.00 100.00 100.00 100.00
			`－` (Note)

~15~

==> picture [471 x 59] intentionally omitted <==

----- Start of picture text -----

Percentage owned by the
Company
Name of Name of Business June 30, December 31, June 30,
Investors Subsidiaries Activities 2025 2024 2024 Note
----- End of picture text -----

Investors	Subsidiaries	Activities	2025	2024	2024	Note
SPT	SciAnda	Research,	100.00	100.00	100.00	`－`
International,	(Changshu)	development
Ltd.	Pharmaceuticals,	and manufacture
	Ltd.	of API and new
		drugs, sales of
		self-produced
		products, etc.
SPT	SciAnda	Import, export	100.00	100.00	100.00	(Note)
International,	Shanghai	and sales of
Ltd.	Biochemical	API and
	Technology,	intermediates,
	Ltd.	etc.

Note : The financial statements of the entity as of and for the six-month periods ended June 30, 2025 and 2024 were not reviewed by independent auditors as the entity did not meet the definition of a significant subsidiary.

C. Subsidiaries not included in the consolidated financial statements: None.
D. Adjustments for subsidiaries with different balance sheet dates: None.
E. Significant restrictions: None.
F. Subsidiaries that have non-controlling interests that are material to the Group: None.

(4) Employee benefits

Defined benefit plans

Pension cost for the interim period is calculated on a year-to-date basis by using the pension cost rate derived from the actuarial valuation at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off events. Also, the related information is disclosed accordingly.

(5) Income tax

The interim period income tax expense is recognised based on the estimated average annual effective income tax rate expected for the full financial year applied to the pretax income of the interim period, and the related information is disclosed accordingly.

5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

There have been no significant changes during the period. Refer to Note 5 of the consolidated financial statements for the year ended December 31, 2024.

~16~

6. DETAILS OF SIGNIFICANT ACCOUNTS

(1) CASH AND CASH EQUIVALENTS

Cash: Cash on hand Checking accounts and demand deposits Cash equivalents: Time deposits Bills under repurchase agreements	June 30,2025 115 $ 104,328 104,443 2,838,500 143,000 2,981,500 3,085,943 $	December31,2024 129 $ 167,117 167,246 3,833,741 165,000 3,998,741 4,165,987 $	June 30,2024 143 $ 193,338
			193,481
			3,816,320 197,000
			4,013,320
			4,206,801 $

A. The Group transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.
B. Details of the Group’s time deposits pledged to others as collateral (listed as “Other financial assets
non-current”) as of June 30, 2025, December 31, 2024, and June 30, 2024 are provided in Note 8, “Pledged assets”.

(2) FINANCIAL ASSETS AND LIABILITIES AT FAIR VALUE THROUGH PROFIT OR LOSS

Items Current items: Financial assets (liabilities) mandatorily measured at fair value through profit or loss Derivatives Non-current items: Financial assets mandatorily measured at fair value through profit or loss Unlisted stocks Valuation adjustment (	June 30,2025 6,758 $ ( 4,620 $ 4,620) ( - $	December31,2024 June 30,2024 1,225) $ 652) ($ 4,620 $ 4,620 $ 4,620) 4,620) ( - $ - $	June 30,2024
			4,620 $ 4,620)
			- $

A. The Group recognised net gain (loss) of $15,769, ($4,667), $12,823 and ($22,684) on financial assets and liabilities at fair value through profit or loss (listed as “Other gains and losses”) for the three-month and six-month periods ended June 30, 2025 and 2024, respectively.

~17~

B. The Group entered into contracts relating to derivative financial assets and liabilities which were not accounted for under hedge accounting. The information is listed below (Units in thousands of currencies indicated):

==> picture [469 x 165] intentionally omitted <==

----- Start of picture text -----

June 30, 2025
Items Contract amount Contract period
Forward foreign exchange contracts USD 11,241 5.2025~9.2025
December 31, 2024
Items Contract amount Contract period
Forward foreign exchange contracts USD 7,830 11.2024~2.2025
June 30, 2024
Items Contract amount Contract period
Forward foreign exchange contracts USD 7,190 4.2024~8.2024
----- End of picture text -----

The Group entered into forward foreign exchange contracts to hedge exchange rate risk of operating activities. However, these forward foreign exchange contracts are not accounted for under hedge accounting.

C. The Group has no financial assets at fair value through profit or loss pledged to others as of June 30, 2025, December 31, 2024, and June 30, 2024.

(3) ACCOUNTS RECEIVABLE, NET

A. The ageing analysis of accounts receivable is as follows: June 30,2025 December31,2024 Accounts receivable 493,878 $ 606,123 $ Less: Loss allowance 90) ( 1,904) ( ( 493,788 $ 604,219 $ June 30,2025 December31,2024 Not past due 377,486 $ 509,007 $ Less than 30 days 116,127 94,992 Between 31 to 90 days 265 308 Between 91 to 180 days - - Over 181 days - 1,816 493,878 $ 606,123 $	June 30,2024 479,388 $ 790) 478,598 $ June 30, 2024 393,725 $ 70,895 7,799 6,969 - 479,388 $

The above ageing analysis is based on past due date.

B. As of June 30, 2025, December 31, 2024, and June 30, 2024, accounts receivable arose from contracts with customers. As of January 1, 2024, the balance of receivables from contracts with customers amounted to $788,452.
C. As of June 30, 2025, December 31, 2024, and June 30, 2024, the Group does not hold any collateral as security.

~18~

D. As of June 30, 2025, December 31, 2024, and June 30, 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the Group’s notes and accounts receivable was the book value amount.
E. Information relating to credit risk of accounts receivable is provided in Note 12(2), “Financial instruments”.

(4) INVENTORIES

instruments”. NVENTORIES
Raw materials Supplies Work in process Finished goods Raw materials Supplies Work in process Finished goods Raw materials Supplies Work in process Finished goods	Allowance for Cost marketprice decline 323,992 $ 60,912) ($ 85,423 4,537) ( 771,034 96,717) ( 1,151,022 273,598) ( 2,331,471 $ 435,764) ($ Allowance for Cost marketprice decline 375,907 $ 64,953) ($ 51,867 4,639) ( 658,527 85,105) ( 1,002,857 261,454) ( 2,089,158 $ 416,151) ($ June 30,2025 June 30,2024 December31,2024	Bookvalue
		263,080 $ 80,886 674,317 877,424
		1,895,707 $
		Book value
		310,954 $ 47,228 573,422 741,403
		1,673,007 $

	Allowance for Cost marketprice decline 393,577 $ 77,105) ($ 48,524 5,657) ( 777,913 96,060) ( 1,022,802 248,918) ( 2,242,816 $ 427,740) ($	Bookvalue
		316,472 $ 42,867 681,853 773,884
		1,815,076 $

~19~

The cost of inventories recognised as expense for the period:

Cost of goods sold Loss on scrap inventory Loss on physical inventory Under applied manufacturing overhead Loss on inventory market price decline Revenue from sale of scraps ( Cost of goods sold Loss on scrap inventory Loss on physical inventory Under applied manufacturing overhead Loss on inventory market price decline Revenue from sale of scraps (	2025 2024 318,611 $ 354,298 $ 3,324 - 30 221 98,247 105,739 3,096 4,471 571) 526) ( 422,737 $ 464,203 $ 2025 2024 613,013 $ 765,180 $ 3,324 - 236 403 218,270 201,959 27,675 22,091 1,039) 913) ( 861,479 $ 988,720 $ For thethree-monthperiods ended June 30, For the six-month periods ended June 30,
	2025 613,013 $ 3,324 236 218,270 27,675 1,039) ( 861,479 $

(5) FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME -

NON-CURRENT

==> picture [487 x 15] intentionally omitted <==

----- Start of picture text -----

Items June 30, 2025 December 31, 2024 June 30, 2024
----- End of picture text -----

Equity instruments Emerging stocks Unlisted stocks Valuation adjustment (	1,156,000 $ 167,673 1,323,673 17,074) ( 1,306,599 $	- $ 167,673 167,673 97,539) ( 70,134 $	- $ 167,673 167,673 118,311) 49,362 $

A. The Group has elected to classify investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments is the book value as of June 30, 2025, December 31, 2024, and June 30, 2024.

A. The Group has elected to classify investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments is the book value as of June 30, 2025, December 31, 2024, and June 30, 2024.	A. The Group has elected to classify investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments is the book value as of June 30, 2025, December 31, 2024, and June 30, 2024.	A. The Group has elected to classify investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments is the book value as of June 30, 2025, December 31, 2024, and June 30, 2024.	A. The Group has elected to classify investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments is the book value as of June 30, 2025, December 31, 2024, and June 30, 2024.	A. The Group has elected to classify investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments is the book value as of June 30, 2025, December 31, 2024, and June 30, 2024.
B. Amounts recognised in other comprehensive income in relation to the financial assets at fair value
through other comprehensive income are listed below:
Equity instruments at fair value through other		For thethree-monthperiods ended June		30,
comprehensiveincome		2025	2024
Fair value change recognised in other
comprehensive income (loss)	($	2,582)	($	3,227)

~20~

Equity instruments at fair value through other		For the six-monthperiods	For the six-monthperiods	ended June 30,
comprehensiveincome		2025		2024
Fair value change recognised in other
comprehensive income (loss)	$	80,465	($	20,611)

C. The Group has no financial assets at fair value through other comprehensive income pledged to others as of June 30, 2025, December 31, 2024, and June 30, 2024.

~21~

(6) PROPERTY, PLANT AND EQUIPMENT

																		Construction in
																		progress and
																		equipment before
					Machinery and			Transportation				Office			Other			acceptance
January 1, 2025			Buildings			equipment			equipment			equipment			equipment			inspection			Total
Cost		$	4,309,016		$	6,194,785		$	29,299		$	254,278		$	173,026		$	194,044		$	11,154,448
Accumulated depreciation	(		2,074,839)	(		4,976,305)	(		22,930)	(		198,727)	(		138,624)			-	(		7,411,425)
Accumulated impairment			-	(		4,134)			-			-			-			-	(		4,134)
		$	2,234,177		$	1,214,346		$	6,369		$	55,551		$	34,402		$	194,044		$	3,738,889
For the six-month period ended
June 30, 2025
At January 1		$	2,234,177		$	1,214,346		$	6,369		$	55,551		$	34,402		$	194,044		$	3,738,889
Additions			-			-			-			25			-			46,168			46,193
Reclassified from prepayments
for equipment			-			-			-			-			-			55,895			55,895
Reclassified upon completion			2,971			180,271			142			26,071			1,622	(		211,077)			-
Reclassified to intangible assets			-			-			-			-			-	(		1,278)	(		1,278)
Reclassified to other non-current assets -
others			-			-			-			-			-	(		5,755)	(		5,755)
Depreciation charge	(		94,411)	(		127,389)	(		1,022)	(		9,854)	(		1,836)			-	(		234,512)
Disposals`－`Cost	(		1,704)	(		20,586)			-	(		5,324)	(		691)			-	(		28,305)
' `－`Accumulated depreciation			783			20,481			-			5,285			622			-			27,171
Reversal of impairment loss			-			63			-			-			-			-			63
Net currency exchange differences	(		61,788)	(		36,313)	(		277)	(		2,357)	(		2,444)	(		4,986)	(		108,165)
At June 30		$	2,080,028		$	1,230,873		$	5,212		$	69,397		$	31,675		$	73,011		$	3,490,196
June 30, 2025
Cost		$	4,213,409		$	6,270,621		$	28,710		$	266,906		$	159,320		$	73,011		$	11,011,977
Accumulated depreciation	(		2,133,381)	(		5,035,677)	(		23,498)	(		197,509)	(		127,645)			-	(		7,517,710)
Accumulated impairment			-	(		4,071)			-			-			-			-	(		4,071)
		$	2,080,028		$	1,230,873		$	5,212		$	69,397		$	31,675		$	73,011		$	3,490,196

~22~

																		Construction in
																		progress and
																		equipment before
					Machinery and			Transportation				Office			Other			acceptance
January 1, 2024			Buildings			equipment			equipment			equipment			equipment			inspection			Total
Cost		$	4,249,075		$	5,998,911		$	26,907		$	244,141		$	165,103		$	77,715		$	10,761,852
Accumulated depreciation	(		1,875,104)	(		4,772,711)	(		21,402)	(		195,193)	(		131,732)			-	(		6,996,142)
Accumulated impairment			-	(		3,014)			-			-			-			-	(		3,014)
		$	2,373,971		$	1,223,186		$	5,505		$	48,948		$	33,371		$	77,715		$	3,762,696
For the six-month period ended
June 30, 2024
At January 1		$	2,373,971		$	1,223,186		$	5,505		$	48,948		$	33,371		$	77,715		$	3,762,696
Additions			-			-			-			-			-			14,368			14,368
Reclassified from prepayments
for equipment			-			-			-			-			-			170,223			170,223
Reclassified upon completion			23,971			152,921			804			12,909			2,947	(		193,552)			-
Depreciation charge	(		93,898)	(		123,057)	(		820)	(		8,483)	(		1,616)			-	(		227,874)
Disposals`－`Cost			-	(		11,284)			-	(		14,486)	(		1,065)			-	(		26,835)
' `－`Accumulated depreciation			-			10,675			-			14,476			994			-			26,145
Net currency exchange differences			23,507			10,669			99			547			856			483			36,161
At June 30		$	2,327,551		$	1,263,110		$	5,588		$	53,911		$	35,487		$	69,237		$	3,754,884
June 30, 2024
Cost		$	4,307,260		$	6,165,904		$	27,924		$	244,934		$	172,037		$	69,237		$	10,987,296
Accumulated depreciation	(		1,979,709)	(		4,899,780)	(		22,336)	(		191,023)	(		136,550)			-	(		7,229,398)
Accumulated impairment			-	(		3,014)			-			-			-			-	(		3,014)
		$	2,327,551		$	1,263,110		$	5,588		$	53,911		$	35,487		$	69,237		$	3,754,884

~23~

A. The Group has not capitalised borrowing costs as part of property, plant and equipment for the three-month and six-month periods ended June 30, 2025 and 2024.
B. The Group’s property, plant and equipment were owner-occupied for the six-month periods ended June 30, 2025 and 2024.
C. As of June 30, 2025, December 31, 2024, and June 30, 2024, the Group has not pledged any property, plant and equipment as collateral.
－
(7) LEASING ARRANGEMENTS LESSEE
A. The Group leases land and buildings and structures. Rental contracts are typically made for periods of 50 (including the option to extend the leases) and 2 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions, with no restrictions other than the use of the subject matter of the lease in accordance with relevant laws and regulations.
B. Short-term leases with a lease term of 12 months or less pertain to office premises and low-value assets pertain to computers.
C. The carrying amount of right-of-use assets and the depreciation charge are as follows:

Land Buildings and structures Land Buildings and structures Land Buildings and structures	June 30,2025 Carryingamount 670,626 $ 8,542 679,168 $	December31,2024 June 30,2024 Carryingamount Carryingamount 684,290 $ 691,861 $ 2,345 335 686,635 $ 692,196 $ For thethree-monthperiods ended June 30,	June 30,2024
			Carryingamount
			691,861 $ 335
			692,196 $
		2025 2024 Depreciationcharge Depreciationcharge 3,953 $ 3,975 $ 1,366 336 5,319 $ 4,311 $ For the six-monthperiods ended June 30,	2024
			Depreciationcharge
			3,975 $ 336
			4,311 $
		2025 Depreciationcharge 7,934 $ 2,044 9,978 $	2024
			Depreciationcharge
			7,941 $ 672
			8,613 $

D. For the three-month and six-month periods ended June 30, 2025 and 2024, the Group’s additions －－－
of right-of-use assets were $ , $ , $8,241 and $ , respectively; the remeasurements of right- －－－
of-use assets were $ , $ , $ and $61,985, respectively.

~24~

E. The information on income and expense accounts relating to lease contracts is as follows:

	For thethree-month	For thethree-month	periods ended June 30,	periods ended June 30,
		2025		2024
Items affecting profit or loss
Interest expense on lease liabilities	$	1,835	$	1,824
Expense on short-term lease contracts		263		124
Expense on leases of low-value assets		619		1,010
		For the six-month periods ended June 30,
		2025		2024
Items affecting profit or loss
Interest expense on lease liabilities	$	3,656	$	3,658
Expense on short-term lease contracts		523		241
Expense on leases of low-value assets		1,467		2,075

F. For the six-month periods ended June 30, 2025 and 2024, the Group’s total cash outflow for leases were $13,272 and $12,198, respectively.

(8) IMPAIRMENT OF NON-FINANCIAL ASSETS

A. For the three-month and six-month periods ended June 30, 2025 and 2024, the Group recognised －－
the reversal of impairment loss amounting to $63, $ , $63 and $ , respectively (listed as “Other gains and losses”) as some of the idle machineries were disposed. For details of accumulated impairment, refer to Note 6(6), “ Property, plant and equipment”.
B. The reversal of impairment loss reported by operating segments is as follows:

==> picture [477 x 245] intentionally omitted <==

----- Start of picture text -----

For the three-month periods ended June 30,
2025 2024
Recognised in other Recognised in other
Recognised comprehensive Recognised comprehensive
Segment in profit or loss income in profit or loss income
ScinoPharm
Taiwan, Ltd. $ 63 $ - $ - $ -
For the six-month periods ended June 30,
2025 2024
Recognised in other Recognised in other
Recognised comprehensive Recognised comprehensive
Segment in profit or loss income in profit or loss income
ScinoPharm
Taiwan, Ltd. $ 63 $ - $ - $ -
----- End of picture text -----

~25~

(9) SHORT-TERM BORROWINGS

Type ofborrowings Bank loans Unsecured loans Type of borrowings Bank loans Unsecured loans Type ofborrowings Bank loans Unsecured loans	June 30,2025 Interest rate Collateral 82,758 $ 2.70%～2.90% None December31,2024 Interest rate Collateral 35,563 $ 2.90%～3.00% None June 30,2024 Interest rate Collateral 8,865 $ 3% None

Refer to Note 6(21), “ Finance costs” for interest expense recognised in profit or loss for the threemonth and six-month periods ended June 30, 2025 and 2024.

(10) OTHER PAYABLES

Accrued salaries and bonuses Payables on equipment Accrued employees’ compensation and directors’ remuneration Cash dividends payable Others	June 30,2025 80,870 $ 72,931 11,704 276,759 149,803 592,067 $	December31,2024 96,725 $ 154,222 46,723 - 200,521 498,191 $	June 30, 2024
			92,887 $ 71,587 29,963 237,222 179,444
			611,103 $

(11) PENSIONS

A. The Company has set up a defined benefit pension plan in accordance with the Labor Standards Law, which applies to all regular employees’ service years prior to the enforcement of the Labor Pension Act (the “Act”) on July 1, 2005 and service years thereafter of employees who chose to continue to be covered under the pension scheme of the Labor Standards Law after the enforcement of the Act. In accordance with the Company's retirement plan, an employee may retire when the employee either (i) attains the age of 55 with 15 years of service, (ii) has more than 25 years of service, (iii) has reached the age of 65, or (iv) is incapacitated to work (compulsory retirement). The employees earn two units for each year of service for the first 15 years, and one unit for each additional year thereafter up to a maximum of 45 units. Any fraction of a year equal to or more than six months shall be counted as one year of service, and any fraction of a year less than six months shall be counted as half a year. According to the provisions, employees who retired due to their duties shall get additional 20%. Pension payments are based on the number of units earned and the average salary of the last six months prior to retirement. Calculation of average salary is in accordance with the Labor Standards Law of the R.O.C. The

~26~

Company contributes monthly an amount equal to 2% of the employees' monthly salaries and wages to the retirement fund deposited with Bank of Taiwan under the name of the independent retirement fund committee. Also, the Company would assess the balance in the aforementioned labor pension reserve account by December 31, every year. If the account balance is not enough to pay the pension calculated by the aforementioned method to the employees expected to qualify for retirement in the following year, the Company will make contribution for the deficit by end of March next year.

(a) The pension costs under the aforementioned defined benefit pension plan of the Company for the three-month and six-month periods ended June 30, 2025 and 2024 were $287, $272, $573 and $545, respectively.
(b) Expected contributions to the defined benefit pension plan of the Company for 2025 amount to $2,762.
B. As a result of the enforcement of the Act, the Company set up a defined contribution pension plan which took effect on July 1, 2005. The local employees are eligible for the defined contribution plan. For employees who choose to be covered under the pension scheme of the Act, the Company contributes monthly an amount of not less than 6% of the employees’ monthly salaries and wages to the employees’ individual pension accounts at the Bureau of Labor Insurance. Pensions are paid by monthly installments or in lump sum based on the accumulated balances of the employees’ individual pension accounts. The subsidiaries in Mainland China (SciAnda (Changshu) Pharmaceuticals, Ltd., and SciAnda Shanghai Biochemical Technology, Ltd.) are subject to a government sponsored defined contribution plan. In accordance with the related Laws of the People’s Republic of China, the subsidiaries in Mainland China contribute monthly 18% of the employees’ monthly salaries and wages to an independent fund administered by the government. Other than the monthly contributions, these subsidiaries do not have further obligations. The other subsidiaries, SPT International, Ltd. and ScinoPharm Singapore Pte Ltd., had no employees. For the three-month and six-month periods ended June 30, 2025 and 2024, the pension costs recognised under the aforementioned defined contribution pension plans were $10,726, $10,392, $21,646 and $20,637, respectively.

(12) SHARE CAPITAL

A. Movements in the number of the Company’s ordinary shares outstanding are as follows (in thousands of shares):

For the six-month periods ended June 30, 2025 2024 At January 1 and June 30 790,739 790,739

B. As of June 30, 2025, the Company’s authorised capital was $10,000,000, and the paid-in capital was $7,907,392 (790,739 thousand shares) with a par value of $10 (in dollars) per share. All proceeds from shares issued have been collected.

~27~

(13) CAPITAL RESERVES

A. Pursuant to the R.O.C. Company Act, capital reserve arising from paid-in capital in excess of par value on issuance of common stocks and donations shall be exclusively used to cover accumulated deficit or, distribute cash or stocks in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Act requires that the capital reserve to be capitalised mentioned above should not exceed 10% of the paid-in capital each year. Capital reserve should not be used to cover accumulated deficit unless the legal reserve is insufficient.
B. Movements on the Company’s capital reserve are as follows:

Share premium Stockoptions Total 1,265,818 $ 28,871 $ 1,294,689 $ 2,067 2,067) ( - 1,267,885 $ 26,804 $ 1,294,689 $ For the six-monthperiod ended June 30,2025 For the six-month period ended June 30, 2024	Share premium Stockoptions Total 1,265,818 $ 28,871 $ 1,294,689 $ 2,067 2,067) ( - 1,267,885 $ 26,804 $ 1,294,689 $ For the six-monthperiod ended June 30,2025 For the six-month period ended June 30, 2024	Share premium Stockoptions Total 1,265,818 $ 28,871 $ 1,294,689 $ 2,067 2,067) ( - 1,267,885 $ 26,804 $ 1,294,689 $ For the six-monthperiod ended June 30,2025 For the six-month period ended June 30, 2024
Share premium 1,265,336 $ 316 1,265,652 $	Stock options 29,353 $ 316) ( 29,037 $	Total
		1,294,689 $ -
		1,294,689 $

(14) SHARE-BASED PAYMENT – EMPLOYEES’ COMPENSATION

A. The Company issued 1.5 million units and 1.5 million units of employee stock options on November 6, 2015 and October 14, 2016, respectively (the ‘Grant Date’). The exercise price of the options was set at $41.65 (in dollars) and $40.55 (in dollars), respectively, which was based on the closing market price of the Company’s common shares on the Grant Dates. Each option gives the holder the right to purchase one share of the Company’s common stocks. The exercise price is subject to further adjustments when there is a change in the number of shares of the Company’s common stocks, the cash dividend of the common stocks is more than 1.5% of the current price per share or there is a decrease in common stocks caused by capital reduction not due to the retirement of treasury share after the Grant Date. Contract period of the employee stock option plans is 10 years, and options are exercisable in 2 years after the Grant Date.

~28~

B. Details of the share-based payment arrangements are as follows:

Options outstanding at beginning of the period Options forfeited ( Options outstanding at end of the period Options exercisable at end of the period Options outstanding at beginning of the period Options forfeited ( Options outstanding at end of the period Options exercisable at end of the period	Weighted-average Number of options exercise price (in thousand units) (indollars) 1,128 36.07 $ 153) 36.07 975 35.33 975 35.33 For the six-monthperiod ended June 30,2025 For the six-month period ended June 30, 2024
	Weighted-average Number of options exercise price (in thousand units) (in dollars) 1,164 36.07 $ 24) 36.30 1,140 36.07 1,140 36.07

C. The expiry date, exercisable shares and exercise prices of the employee stock options at balance sheet date are as follows:

The expiry date, exercisable shares and exercise prices of the employee stock options at balance sheet date are as follows:	The expiry date, exercisable shares and exercise prices of the employee stock options at balance sheet date are as follows:	The expiry date, exercisable shares and exercise prices of the employee stock options at balance sheet date are as follows:	The expiry date, exercisable shares and exercise prices of the employee stock options at balance sheet date are as follows:
Note: Exercise price is adjusted according to a specific formula. Grantdate Expiry date No. of stocks (unit in thousands) Exercise price (in dollars) (Note) No. of stocks (unit in thousands) Exercise price (in dollars) (Note) 11.6.2015 11.5.2025 445 35.06 $ 515 35.80 $ 10.14.2016 10.13.2026 530 35.55 613 36.30 Grantdate Expiry date No. of stocks (unit in thousands) Exercise price (in dollars) (Note) 11.6.2015 11.5.2025 527 35.80 $ 10.14.2016 10.13.2026 613 36.30 June 30,2025 December31,2024 June 30,2024
	515 613 No. of stocks (unit in thousands) June 30,	515 613 June 30,	35.80 $ 36.30 Exercise price (in dollars) (Note) 2024
			35.80 $ 36.30

~29~

D. The fair value of the Group’s employee stock options on Grant Date was evaluated using the combination of Hull & White and the Ritchken trinomial option valuation model. Related information is as follows:

combinationofHull & information is as follows:	White and the Ritc	hken trin	omial option valuation model. Related
Type of arrangement Grantdate Employee 11.6.2015 stock options Employee 10.14.2016 stock options	Stock Exercise price price (indollars) (indollars) 41.65 $ 41.65 $ 40.55 40.55	Price volatility	Fair value Option Expected Interest per unit life dividends rate (in dollars) 10 years 1.5% 1.2936% 13.799 $ 10 years 1.5% 0.9223% 13.171
		37.63% (Note) 37.20% (Note)

Note: According to daily returns of the Company’s stock for the previous year, the annualised volatility were 37.63% and 37.20%, respectively.

(15) RETAINED EARNINGS

A. Pursuant to the amended R.O.C. Company Act, the current year’s after-tax earnings should be used initially to cover any accumulated deficit; thereafter 10% of the remaining earnings should be set aside as legal reserve until the balance of legal reserve is equal to that of paid-in capital. The legal reserve shall be exclusively used to cover accumulated deficit, to issue new stocks, or to distribute cash to shareholders in proportion to their share ownership. The use of legal reserve for the issuance of stocks or cash dividends to shareholders in proportion to their share ownership is permitted provided that the distribution of the reserve is limited to the portion in excess of 25% of the Company’s paid-in capital.
B. According to the Articles of Incorporation of the Company, since the Company is in a changeable industry environment and the life cycle of the Company is in a stable growth, the appropriation of earnings should consider fund requirements and capital budget to decide how much earnings will be kept or distributed and how much cash dividends will be distributed. According to the Company’s Articles of Incorporation, 10% of the annual net income, except for offsetting any loss of prior years and paying all taxes and dues according to laws, after adding items other than net profit after taxes for the year into undistributed surplus earnings of current year, 10% of the remaining shall be set aside as legal reserve. The remaining net income and the unappropriated retained earnings from prior years can be distributed in accordance with a resolution passed during a meeting of the Board of Directors and approved at the stockholders’ meeting. Of the amount to be distributed by the Company, stockholders’ dividends shall comprise 50% to 100% of the unappropriated retained earnings, and the percentage of cash dividends shall not be less than 30% of dividends distributed.
C. In accordance with the regulations, the Company shall set aside special reserve from the debit balance on other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings. The amounts previously set aside by the Company as special reserve on initial application of IFRSs in accordance with Order No. Jin-Guan-Zheng-Fa-Zi Letter No.

~30~

1010012865, dated April 6, 2012, shall be reversed proportionately when the relevant assets are used, disposed of or reclassified subsequently. As of June 30, 2025, the amount of special reserve on initial application of IFRSs provided in accordance with the order from Financial Supervisory Committee was $22,829.

D. The Company recognised cash dividends distributed to owners amounting to $237,222 ($0.3 (in dollars) per share) for the year ended December 31, 2024. On May 28, 2025, the stockholders approved the distribution of cash dividends of $276,759 ($0.35 (in dollars) per share) from 2024 earnings. As of June 30, 2025 and 2024, dividends have not yet been distributed (listed as “Other Payables”).

(16) OTHER EQUITY ITEMS

Payables”). OTHER EQUITY ITEMS
			For the six-monthperiod ended June30,				2025
					Unrealised loss
		Currencytranslation			onvaluation		Total
At January 1	($		28,638)	($	97,539)	($	126,177)
Revaluation			-		80,465		80,465
Currency translation differences
- Group	(		141,275)		-	(	141,275)
At June 30	($		169,913)	($	17,074)	($	186,987)
			For the six-month period ended June 30,				2024
					Unrealised loss
		Currencytranslation			onvaluation		Total
At January 1	($		88,156)	($	97,700)	($	185,856)
Revaluation			-	(	20,611)	(	20,611)
Currency translation differences
- Group			50,462		-		50,462
At June 30	($		37,694)	($	118,311)	($	156,005)

(17) OPERATING REVENUE

A. Disaggregation of revenue from contracts with customers

The Group derives revenue from the transfer of goods at a point in time and the rendering of services over time in the following major product lines:

For the three-month period ended June 30,2025 Timing of revenue recognition: At a point in time Over time	API Income 640,697 $ - 640,697 $	Injection Product Income 54,869 $ - 54,869 $	Technical Service Income - $ 28,486 28,486 $	Other Operating Income 23,469 $ - 23,469 $	Total
					719,035 $ 28,486
					747,521 $

~31~

==> picture [460 x 392] intentionally omitted <==

----- Start of picture text -----

For the three-month Injection Technical Other
period ended API Product Service Operating
June 30, 2024 Income Income Income Income Total
Timing of revenue
recognition:
-
At a point in time $ 712,397 $ 7,729 $ $ 1,414 $ 721,540
Over time - - 40,819 - 40,819
$ 712,397 $ 7,729 $ 40,819 $ 1,414 $ 762,359
For the six-month Injection Technical Other
period ended API Product Service Operating
June 30, 2025 Income Income Income Income Total
Timing of revenue
recognition:
-
At a point in time $ 1,255,050 $ 70,965 $ $ 25,278 $ 1,351,293
Over time - - 82,593 - 82,593
$ 1,255,050 $ 70,965 $ 82,593 $ 25,278 $ 1,433,886
For the six-month Injection Technical Other
period ended API Product Service Operating
June 30, 2024 Income Income Income Income Total
Timing of revenue
recognition:
-
At a point in time $ 1,510,047 $ 38,479 $ $ 35,119 $ 1,583,645
Over time - - 61,940 - 61,940
$ 1,510,047 $ 38,479 $ 61,940 $ 35,119 $ 1,645,585
----- End of picture text -----

B. The Group has recognised the following revenue-related contract assets and liabilities:

Contract assets - current Contract liabilities - current	June 30, 2025 - $ 166,477 $	December 31, 2024 29,397 $ 119,396 $	June 30, January 1, 2024 2024 - $ - $ 144,776 $ 110,967 $

C. The revenue recognised that was included in the contract liability balance at the beginning of the period amounted to $13,328, $20,832, $55,854 and $58,023 for the three-month and six-month periods ended June 30, 2025 and 2024, respectively.

(18) INTEREST INCOME

For the three-month periods ended June 30,

	For thethree-monthperiods ended June 30,	ods ended June 30,
Interest income from bank deposits Interest income from bank deposits	2025 2024 13,341 $ 16,573 $ For the six-monthperiods ended June 30,	2024
		16,573 $
	2025 29,116 $	2024
		30,174 $

~32~

(19) OTHER INCOME

OTHER INCOME
			For thethree-monthperiods ended June 30,
			2025		2024
Other income		$	554	$		227
			For the six-monthperiods ended June			30,
			2025		2024
Other income		$	877	$		2,070
OTHER GAINS AND LOSSES
			For thethree-monthperiods ended June 30,
			2025		2024
Net gain (loss) on financial assets/liabilities at		$	15,769	($		4,667)
fair value through profit or loss
Gain (loss) on disposal of property, plant
and equipment			172	(		599)
Gain on reversal of impairment loss			63			-
Net currency exchange (loss) gain	(		61,152)			10,776
Others	(		53)	(		1,202)
	($		45,201)		$	4,308
			For the six-monthperiods ended June			30,
			2025		2024
Net gain (loss) on financial assets/liabilities at		$	12,823	($		22,684)
fair value through profit or loss
Gain (loss) on disposal of property, plant
and equipment			103	(		690)
Gain on reversal of impairment loss			63			-
Net currency exchange (loss) gain	(		54,021)			39,584
Others	(		818)	(		2,083)
	($		41,850)		$	14,127

(20) OTHER GAINS AND LOSSES

~33~

(21) FINANCE COSTS

For the three-month periods ended June 30,

2025 2024

	2025 2024 For thethree-monthperiods ended June 30,	2025 2024 For thethree-monthperiods ended June 30,
Interest expense: Bank loans Interest on lease liabilities Interest expense: Bank loans Interest on lease liabilities	434 $ 198 $ 1,835 1,824 2,269 $ 2,022 $ 2025 2024 744 $ 409 $ 3,656 3,658 4,400 $ 4,067 $ For the six-month periods ended June 30,
		4,067 $

(22) EXPENSES BY NATURE

EXPENSES BY NATURE
Employee benefit expenses Depreciation of property, plant and equipment Depreciation of right-of-use assets Amortisation Employee benefit expenses Depreciation of property, plant and equipment Depreciation of right-of-use assets Amortisation Employee benefit expenses Depreciation of property, plant and equipment Depreciation of right-of-use assets Amortisation	For thethree-monthperiod ended June30,2025
	Operating costs Operating expenses Total 161,273 $ 89,615 $ 250,888 $ 99,196 18,031 117,227 - 5,319 5,319 727 4,312 5,039 For the three-month period ended June 30, 2024		Total
	Operating costs Operating expenses Total 166,499 $ 87,292 $ 253,791 $ 98,055 16,862 114,917 - 4,311 4,311 697 1,536 2,233 For the six-month period ended June 30, 2025		Total
	Operating costs 325,356 $ 200,064 - 1,939	Operating expenses 170,511 $ 34,448 9,978 8,154	Total
			495,867 $ 234,512 9,978 10,093

~34~

Operating costs Operating expenses Total 332,873 $ 175,311 $ 508,184 $ 194,023 33,851 227,874 - 8,613 8,613 1,382 3,015 4,397 For the six-monthperiod ended June 30,2024 For thethree-monthperiod ended June 30,2025	Operating costs Operating expenses Total 332,873 $ 175,311 $ 508,184 $ 194,023 33,851 227,874 - 8,613 8,613 1,382 3,015 4,397 For the six-monthperiod ended June 30,2024 For thethree-monthperiod ended June 30,2025	Operating costs Operating expenses Total 332,873 $ 175,311 $ 508,184 $ 194,023 33,851 227,874 - 8,613 8,613 1,382 3,015 4,397 For the six-monthperiod ended June 30,2024 For thethree-monthperiod ended June 30,2025
Operating costs Operating expenses Total 134,972 $ 74,211 $ 209,183 $ 12,230 6,420 18,650 7,419 3,594 11,013 6,652 5,390 12,042 161,273 $ 89,615 $ 250,888 $ For thethree-monthperiod ended June 30,2024		Total
		209,183 $ 18,650 11,013 12,042
		250,888 $
Operating costs Operating expenses Total 139,986 $ 73,716 $ 213,702 $ 12,227 5,890 18,117 7,525 3,139 10,664 6,761 4,547 11,308 166,499 $ 87,292 $ 253,791 $ For the six-month period ended June 30, 2025		Total
		213,702 $ 18,117 10,664 11,308
		253,791 $
Operating costs Operating expenses Total 271,170 $ 141,255 $ 412,425 $ 25,157 11,711 36,868 15,367 6,852 22,219 13,662 10,693 24,355 325,356 $ 170,511 $ 495,867 $ For the six-monthperiod ended June 30,2024		Total
		412,425 $ 36,868 22,219 24,355
		495,867 $
Operating costs 280,229 $ 24,639 15,150 12,855 332,873 $	Operating expenses 148,437 $ 11,236 6,032 9,606 175,311 $	Total
		428,666 $ 35,875 21,182 22,461
		508,184 $

(23) EMPLOYEE BENEFIT EXPENSES

~35~

A. According to the Articles of Incorporation of the Company, a ratio of distributable profit of the current year, after covering accumulated losses, shall be distributed as employees’ compensation and directors’ remuneration. The ratio shall not be lower than 2% for employees’ compensation (compensation for grassroots employees shall not be less than 1%) and shall not be higher than 2% for directors’ remuneration.
B. For the three-month and six-month periods ended June 30, 2025 and 2024, the employees’ compensation was accrued at $4,668, $9,021, $10,421 and $26,524, respectively, while the directors’ remuneration was accrued at $547, $1,199, $1,283 and $3,439, respectively. The aforementioned amounts were recognised in salary expenses and were estimated and accrued based on the earnings of current period and the percentage specified in the Articles of Incorporation of the Company. The actual amount approved at the Board of Directors’ meeting for employees’ compensation and directors’ remuneration for 2024 was $46,723, which was the same as the amount recognised in the 2024 financial statements. The employees’ compensation was distributed in the form of cash for 2024. Information about the appropriation of employees’ compensation and directors’ remuneration by the Company as resolved by the Board of Directors will be posted in the “Market Observation Post System” at the website of the Taiwan Stock Exchange.

(24) INCOME TAX

A. Income tax expense

Components of income tax expense:

Exchange. COME TAX Income tax expense Components of income tax expense:
Total current tax Origination and reversal of temporary differences Current income tax: Income tax for the period prior year’s income tax Deferred income tax: Under (over) provision of Income tax expense	2025 2024 10,632 $ 16,025 $ 383 2,967) ( 11,015 13,058 1,474 2,292 12,489 $ 15,350 $ For thethree-monthperiods ended June 30,
	2025 10,632 $ 383 ( 11,015 1,474 12,489 $

~36~

			For the six-monthperiods	For the six-monthperiods	For the six-monthperiods	ended June 30,
			2025			2024
Current income tax:
Income tax for the period		$	34,796		$	45,221
Under (over) provision of
prior year’s income tax			383	(		2,967)
Total current tax			35,179			42,254
Deferred income tax:
Origination and reversal of temporary
differences	(		11,169)			8,129
Income tax expense		$	24,010		$	50,383

B. The Company’s income tax returns through 2023 have been assessed and approved by the Tax Authority, and there were no disputes existing between the Company and the Authority as of August 6, 2025.

(25) EARNINGS PER SHARE (“EPS”)

August 6, 2025. EARNINGS PER SHARE (“EPS”)
Basic earnings per share Profit attributable to ordinary stockholders of the parent Diluted earnings per share Profit attributable to ordinary stockholders of the parent Assumed conversion of all dilutive potential ordinary shares Employees’ stock options Employees’ compensation Profit attributable to ordinary stockholders of the parent plus assumed conversion of all dilutive potential ordinary shares	For thethree-monthperiod ended June 30,2025
	Amount after tax 34,201 $ 34,201 $ - - 34,201 $	Weighted average number of shares outstanding (sharesin thousands) 790,739 790,739 - 616 791,355	EPS (indollars)
			0.04 $
			0.04 $

~37~

For thethree-monthperiod ended June 30,2024	For thethree-monthperiod ended June 30,2024	For thethree-monthperiod ended June 30,2024
Weighted average number of shares outstanding Amount after tax (sharesin thousands) 74,882 $ 790,739 74,882 $ 790,739 - - - 924 74,882 $ 791,663 For the six-monthperiod ended June 30,		EPS (indollars)
		0.09 $
		0.09 $
		2025
Amount after tax 80,224 $ 80,224 $ - - 80,224 $	Weighted average number of shares outstanding (sharesin thousands) 790,739 790,739 - 1,185 791,924	EPS (indollars)
		0.10 $
		0.10 $

~38~

Basic earnings per share Profit attributable to ordinary stockholders of the parent Diluted earnings per share Profit attributable to ordinary stockholders of the parent Assumed conversion of all dilutive potential ordinary shares Employees’ stock options Employees’ compensation Profit attributable to ordinary stockholders of the parent plus assumed conversion of all dilutive potential ordinary shares	Weighted average number of shares outstanding Amount after tax (sharesin thousands) 214,905 $ 790,739 214,905 $ 790,739 - - - 1,366 214,905 $ 792,105 For the six-monthperiod ended June 30,	EPS (indollars) 2024
		0.27 $
		0.27 $

For the three-month and six-month periods ended June 30, 2025 and 2024, some abovementioned stock options issued were anti-dilutive; therefore they were not included in the diluted EPS calculation.

(26) SUPPLEMENTAL CASH FLOW INFORMATION

A. Investing activities with partial cash payments:

Purchase of property, plant and equipment Add: Beginning balance of payable on equipment (listed as “Other payables”) Less: Ending balance of payable on equipment (listed as “Other payables”) ( Cash paid for acquisition of property, plant and equipment	2025 2024 46,193 $ 14,368 $ 102,971 56,759 56,799) 41,703) ( 92,365 $ 29,424 $ For the six-monthperiods ended June 30,

~39~

				For the six-monthperiods ended June 30,	For the six-monthperiods ended June 30,	For the six-monthperiods ended June 30,	For the six-monthperiods ended June 30,	For the six-monthperiods ended June 30,
				2025			2024
Purchase of prepayments for equipment			$		35,968	$		132,742
Add: Beginning balance of payable
on equipment (listed as “Other payables”)					51,251			-
Less: Ending balance of payable
on equipment (listed as “Other payables”)		(			16,132)	(		29,884)
Cash paid for prepayments for equipment			$		71,087	$		102,858
B. Operating, investing and financing activities with no cash flow					effects:
				For the six-month periods ended June 30,
				2025			2024
Inventory reclassified to prepayments			$		2,051	$		-
Property, plant and equipment reclassified to
intangible assets			$		1,278	$		-
Property, plant and equipment reclassified to
other non-current assets - others			$		5,755	$		-
Prepayments for equipment reclassified to
property, plant and equipment			$		55,895	$		170,223
Prepayments for equipment reclassified to
other non-current assets - others			$		51,732	$		-
Cash dividends declared but not paid			$		276,759	$		237,222
CHANGES IN LIABILITIES FROM FINANCING			ACTIVITIES
					Guarantee		Liabilities from
For the six-month period ended Short-term				Lease	deposits			financing
June 30,2025 borrowings				liabilities	received		activities-gross
At January 1, 2025 35,563 $		$		639,980	$	3,992	$	679,535
Changes in cash flow from
financing activities 54,047	(			7,626)	(	140)		46,281
Impact of changes in
foreign exchange rate 6,852) (				-	(	203)	(	7,055)
Changes in other
non-cash items -				8,241		-		8,241
At June 30, 2025 82,758 $		$		640,595	$	3,649	$	727,002

(27) CHANGES IN LIABILITIES FROM FINANCING ACTIVITIES

~40~

									Guarantee	Liabilities from	Liabilities from
For the six-month period ended			Short-term			Lease			deposits		financing
June 30, 2024			borrowings			liabilities			received	activities-gross
At January 1, 2024		$	32,137		$	587,787		$	1,297	$	621,221
Changes in cash flow from
financing activities	(		24,083)	(		6,224)	(		442)	(	30,749)
Impact of changes in
foreign exchange rate			811			-			38		849
Changes in other
non-cash items			-			61,985			-		61,985
At June 30, 2024		$	8,865		$	643,548		$	893	$	653,306

7. RELATED PARTY TRANSACTIONS

(1) Parent and ultimate controlling party

The ultimate parent and ultimate controlling party of the Company is Uni-President Enterprises Corp.

(2) Names of related parties and relationship

Names of related parties Uni-President Enterprises Corp. President Securities Corp. President Transnet Corp. President Tokyo Corp. Mech-President Corp. President Chain Store Corp. President Chain Store Tokyo Marketing Corp. President Information Corp. Duskin Serve Taiwan Co., Ltd. Uni-President Enterprises (China) Investment Corp. Uni-President Shanghai Pearly Century Co., Ltd.

Relationship with the Company Ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company

(3) Significant transactions and balances with related parties

A. Property transactions

Property transactions
Acquisition of property, plant and equipment `－`Ultimate parent company `－`Associate of ultimate parent company	For thethree-monthperiods ended June 30,
	2025 16 $ 286 302 $	2024
		- $ 1,017
		1,017 $

~41~

For the six-month periods ended June 30,

Acquisition of property, plant and equipment

－ Ultimate parent company
－ Associate of ultimate parent company

F	or the six-monthpe	riods e	nded June 30,
	2025		2024
$	41	$	-
	286		1,017
$	327	$	1,017

B. Other expenses

For the three-month periods ended June 30,

Management service fees:

－ Ultimate parent company
－ Associate of ultimate parent company

Management service fees:

－ Ultimate parent company
－ Associate of ultimate parent company

==> picture [234 x 186] intentionally omitted <==

----- Start of picture text -----

2025 2024
$ 2,067 $ 1,744
910 776
$ 2,977 $ 2,520
For the six-month periods ended June 30,
2025 2024
$ 2,234 $ 1,912
1,503 1,521
$ 3,737 $ 3,433
----- End of picture text -----

(4) Key management compensation

Key management compensation
Salaries and other short-term employee benefits Post-employment benefits Termination benefits Salaries and other short-term employee benefits Post-employment benefits Termination benefits	2025 2024 10,785 $ 13,542 $ 121 153 400 399 11,306 $ 14,094 $ For thethree-monthperiods ended June 30, For the six-monthperiods ended June 30,
	2025 21,956 $ 241 800 22,997 $	2024
		28,832 $ 314 796
		29,942 $

~42~

8. PLEDGED ASSETS

Details of the Group’s assets pledged as collateral are as follows:

Assets June 30, 2025 December 31, 2024 June 30, 2024 Purpose of collateral Pledged time deposits $ 30,940 $ 30,940 $ 30,940 Performance guarantee, (Note) customs duty and guarantee for credit card

Note : Listed as “Other financial assets - non-current”.

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT

COMMITMENTS

(1) As of June 30, 2025, December 31, 2024, and June 30, 2024, the Group’s remaining balance due for construction in progress and prepayments for equipment were $7,202, $43,512 and $83,815, respectively.
(2) The amounts of endorsements and guarantees for subsidiaries were as follows:

Nature June 30, 2025 December 31, 2024 June 30, 2024 SciAnda (Changshu) Guarantee for Pharmaceuticals, Ltd. financing amount $ - $ 179,661 $ 178,608

As of June 30, 2025, December 31, 2024, and June 30, 2024, the actual amount drawn down for endorsements and guarantees to subsidiaries was $ － .

10. SIGNIFICANT DISASTER LOSS

None.

11. SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

None.

12. OTHERS

(1) Capital management

The Group’s objectives on managing capital are to safeguard the Group’s ability to continue as a going concern in order to provide returns for shareholders, to maintain an optimal capital structure, to reduce the cost of capital and to maintain an adequate capital structure to enable the expansion and enhancement of equipment. In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return of capital to shareholders, and issue new shares or sell assets to reduce debts.

(2) Financial instruments

A. Financial instruments

For details of the Group’s financial instruments by category, refer to Note 6.

B. Risk management policies
(a) The Group’s activities expose it to a variety of financial risks: market risk (including foreign exchange risk, price risk and interest rate risk), credit risk and liquidity risk.

~43~

(b) The Group’s treasury identifies, evaluates and hedges financial risks closely with the Group’s operating units. The Board provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as use of derivative financial instruments and investment of excess liquidity.
(c) Information about derivative financial instruments that are used to hedge financial risk are provided in Note 6(2), “Financial assets and liabilities at fair value through profit or loss”.
C. Significant financial risks and degrees of financial risks
(a) Market risk
- I. Foreign exchange rate risk
- (i) The Group operates internationally and is exposed to foreign exchange risk arising from the transactions of the Company and its subsidiaries used in various functional currency, primarily with respect to USD. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities.
- (ii) To manage their foreign exchange risk arising from future commercial transactions and recognised assets and liabilities, entities in the Group are required to hedge their foreign exchange risk exposure using forward foreign exchange contracts. However, the Group does not adopt hedging accounting. Details of financial assets or liabilities at fair value through profit or loss are provided in Note 6(2), “Financial assets and liabilities at fair value through profit or loss”.
- (iii) The Group’s businesses involve some non-functional currency operations (the Company’s and certain subsidiaries’ functional currency: NTD; other subsidiaries’ functional currency: CNY). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations is as follows:

fluctuations is as follows:
(Foreign currency: functional currency) Financial assets Monetary items USD:NTD Financial liabilities Monetary items USD:NTD	June 30,2025
	Foreign currency amount(in thousands) 15,733 $ 1,368	Exchangerate 29.30 29.30	Book value (NTD)
			460,977 $ 40,082

~44~

(Foreign currency: functional currency) Financial assets Monetary items USD:NTD CNY:NTD Financial liabilities Monetary items USD:NTD GBP:NTD EUR:NTD JPY:NTD (Foreign currency: functional currency) Financial assets Monetary items USD:NTD Financial liabilities Monetary items USD:NTD CNY:NTD	Foreign currency amount(in thousands) Exchangerate 19,110 $ 32.79 8,827 4.492 712 32.79 173 41.19 48 34.14 5,264 0.210 Foreign currency amount(in thousands) Exchangerate 16,766 $ 32.45 162 32.45 750 4.465 June 30,2024 December31,2024	Book value (NTD)
		626,617 $ 39,651 23,346 7,126 1,639 1,105 Book value (NTD)
		544,057 $ 5,257 3,349

(iv) As of June 30, 2025 and 2024, if the NTD:USD exchange rate appreciates/depreciates by 5% with all other factors remaining constant, the Group’s net profit after tax for the six-month periods ended June 30, 2025 and 2024 would increase/decrease by $16,836 and $21,552, respectively. If the exchange rate of NTD to other currencies had appreciated/depreciated by 5% with all other factors remaining constant, the effect on the Group’s net profit after tax for the six-month periods ended June 30, 2025 and 2024 is immaterial.
(v) Total exchange (loss) gain including realised and unrealised arising from significant foreign exchange variation on the monetary items held by the Group for the three-month and six-month periods ended June 30, 2025 and 2024 amounted to ($61,152), $10,776, ($54,021) and $39,584 respectively.

~45~

II. Price risk

(i) The Group’s equity securities, which are exposed to price risk, are the held financial assets and liabilities at fair value through profit or loss and financial assets at fair value through other comprehensive income. To manage its price risk arising from investments in equity securities, the Group diversifies its portfolio and set stop-loss amounts for these instruments. The Group expects no significant market risk.
(ii)The Group’s investments in equity securities comprise equity securities issued by the domestic and foreign companies. The prices of equity securities would change due to the change of the future value of investee companies. If the prices of these equity securities had increase/decrease by 5% with all other variables held constant, other components of equity would have increased/decreased by $65,330 and $2,468, respectively, as a result of other comprehensive income on equity investments classified as at fair value through other comprehensive income.
III. Cash flow and fair value interest rate risk
(i) The Group’s main interest rate risk arises from short-term borrowings with variable rates and exposes the Group to cash flow interest rate risk. During the six-month periods ended June 30, 2025 and 2024, the Group’s borrowings at variable rate were denominated in CNY.
(ii) The Group’s borrowings are measured at amortised cost. The borrowings are periodically contractually repriced and to that extent are also exposed to the risk of future changes in market interest rates.
(iii) If the borrowing interest rates had increased/decreased by 10% with all other variables held constant, the effect on post-tax profit for the six-month periods ended June 30, 2025 and 2024 is immaterial.

(b) Credit risk

I. Credit risk refers to the risk of financial loss to the Group arising from default by the clients or counterparties of financial instruments on the contract obligations. The main factor is that counterparties could not repay in full the accounts receivable based on the agreed terms.
II. The Group manages its credit risk taking into consideration the entire group’s concern. For banks and financial institutions, only independently rated parties with a minimum rating of 'A' are accepted. According to the Group’s credit policy, each local entity in the Group is responsible for managing and analysing the credit risk for each of their new clients before standard payment and delivery terms and conditions are offered. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the Board of Directors. The utilisation of credit limits is regularly monitored.

~46~

III. The Group adopts the following assumption under IFRS 9: If the contract payments were past due over 30 days based on the terms, there has been a significant increase in credit risk on that instrument since initial recognition.
IV. The Group manages its credit risk, whereby if the contract payments are past due over 180 days based on the terms, there has been impairment.
V. The Group classifies customers’ accounts receivable in accordance with the credit rating of the customer and credit risk on trade. The Group applies the simplified approach using the provision matrix to estimate expected credit loss, and use the forecastability to adjust historical and timely information to assess the default possibility of accounts receivable. Movements in relation to the Group applying the simplified approach to provide loss allowance for accounts receivable are as follows:

		For the six-month periods	For the six-month periods	For the six-month periods	ended June 30,
		2025			2024
At January 1		$	1,904	$	231
Expected credit (gain) loss	(		1,814)		555
Impact of foreign exchange rate			-		4
At June 30		$	90	$	790

(c) Liquidity risk

I. Cash flow forecasting is performed by the Group’s treasury department which monitors rolling forecasts of the Group’s liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities at all times so that the Group does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities.
II. The Group has undrawn borrowing facilities amounting to $4,945,244, $4,970,318 and $5,134,380 as of June 30, 2025, December 31, 2024, and June 30, 2024, respectively.
III. The following table comprises the Group’s non-derivative financial liabilities and derivative financial liabilities with gross-amount settlement that are grouped by their maturity. Non-derivative financial liabilities are analysed from the balance sheet date to the contract maturity date, and derivative financial liabilities are analysed from the balance sheet date to the expected maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

~47~

June 30,2025 Short-term borrowings Notes payable Accounts payable Other payables Lease liabilities Guarantee deposits received December31,2024 Short-term borrowings Notes payable Accounts payable Other payables Lease liabilities Guarantee deposits received Derivative financial liabilities: Forward exchange contracts June 30,2024 Short-term borrowings Notes payable Accounts payable Other payables Lease liabilities Guarantee deposits received Derivative financial liabilities: Forward exchange contracts Non-derivative financial liabilities: Non-derivative financial liabilities: Non-derivative financial liabilities:	Less than 1year 83,928 $ 20 150,765 592,067 23,963 - Less than 1year 36,174 $ 1,211 80,959 498,191 19,764 - 1,225 Less than 1year 9,083 $ 2,034 147,324 611,103 18,740 - 652	Between 1 and2years - $ - - - 21,539 3,649 Between 1 and2years - $ - - - 19,422 3,992 - Between 1 and 2 years - $ - - - 18,398 893 -	Between 2 and 5 years - $ - - - 55,195 - Between 2 and 5 years - $ - - - 55,195 - - Between 2 and 5 years - $ - - - 55,195 - -	More than 5 years
				- $ - - - 708,330 - More than 5 years
				- $ - - - 717,529 - - More than 5 years
				- $ - - - 726,728 - -

(3) Fair value information

A. The different levels that the inputs to valuation techniques are used to measure fair value of financial and non-financial instruments have been defined as follows:

~48~

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. A market is regarded as active where a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. The fair value of the Group’s investment in private placement of emerging stocks and foreign exchange contracts is included in Level 2.
Level 3: Unobservable inputs for the asset or liability. The fair value of the Group’s investment in equity investment without active market is included in Level 3.
B. Financial instruments not measured at fair value
The carrying amounts of cash and cash equivalents, contract assets, accounts receivable, other receivables, guarantee deposits paid, other financial assets - non-current, short-term borrowings, notes payable, accounts payable, other payables and guarantee deposits received are approximate to their fair values.
C. The related information on financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets and liabilities are as follows:

June 30,2025 Assets: Recurring fair value measurements Financial assets at fair value through profit or loss Derivative instruments Financial assets at fair value through other comprehensive income Equity securities December31,2024 Assets: Recurring fair value measurements Financial assets at fair value through other comprehensive income Equity securities Liabilities: Financial liabilities at fair value through profit or loss Derivative instruments	Level 1 - $ - $ Level 1 - $ - $	Level 2 6,758 $ 1,250,064 $ Level 2 - $ 1,225 $	Level3 - $ 56,535 $ Level3 70,134 $ - $	Total
				6,758 $
				1,306,599 $
				Total
				70,134 $
				1,225 $

~49~

June 30,2024 Assets: Recurring fair value measurements Financial assets at fair value through other comprehensive income Equity securities Liabilities: Recurring fair value measurements Financial liabilities at fair value through profit or loss Derivative instruments	Level 1 - $ - $	Level 2 - $ 652 $	Level3 Total 49,362 $ 49,362 $ - $ 652 $

D. The methods and assumptions the Group used to measure fair value are as follows:
(a) The fair value of other financial instruments is measured by using valuation techniques or by reference to counterparty quotes. The fair value of financial instruments measured by using valuation techniques can be referred to current fair value of instruments with similar terms and characteristics in substance, discounted cash flow method or other valuation methods, including calculated by applying model using market information available at the consolidated balance sheet date.
(b) When assessing non-standard and low-complexity financial instruments, for example, debt instruments without active market, interest rate swap contracts, foreign exchange swap contracts and options, the Group adopts valuation technique that is widely used by market participants. The inputs used in the valuation method to measure these financial instruments are normally observable in the market.
(c) Forward foreign exchange contracts are usually valued based on the current forward exchange rate.
E. For the six-month periods ended June 30, 2025 and 2024, there was no transfer between Level 1 and Level 2.
F. The following chart is the movement of Level 3 for the six-month periods ended June 30, 2025 and 2024:

and 2024:
At January 1 Loss recognised in other comprehensive loss ( At June 30	For the six-monthperiods ended June 30,
	2025 Equityinstrument 70,134 $ 13,599) ( 56,535 $	2024
		Equityinstrument
		69,973 $ 20,611)
		49,362 $

For the six-month periods ended June 30, 2025 and 2024, there was no transfer in (out) of Level 3.

~50~

G. The Group’s valuation procedures for fair value measurements is categorised within Level 3, which is to verify independent fair value of financial instruments. Such assessment is to ensure the valuation results are reasonable by applying independent information to make results close to current market conditions, confirming the resource of information is independent, reliable and in line with other resources and represented as the exercisable price, and frequently assess to make any other necessary adjustments to the fair value.
H. The following is the qualitative information of significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement:

value measurement:
Fair value at June 30,2025 Non-derivative equity instrument: Unlisted shares 56,535 $ Fair value at December31,2024 Non-derivative equity instrument: Unlisted shares 70,134 $ Fair value at June 30,2024 Non-derivative equity instrument: Unlisted shares 49,362 $	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship of inputs to fairvalue
	Net asset value Valuation technique	Discount for lack of marketability Significant unobservable input	50% Range (weighted average)	The higher the discount for lack of marketability, the lower the fair value Relationship of inputs to fairvalue
	Net asset value Valuation technique	Discount for lack of marketability Significant unobservable input	50% Range (weighted average)	The higher the discount for lack of marketability, the lower the fair value Relationship of inputs to fairvalue
	Net asset value	Discount for lack of marketability	50%	The higher the discount for lack of marketability, the lower the fair value

~51~

I. The Group has carefully assessed the valuation models and assumptions used to measure fair value. However, use of different valuation models or assumptions may result in different measurement. If the discount for lack of marketability increased or decreased by 1% for Level 3, the effect on other comprehensive income for the six-month periods ended June 30, 2025 and 2024 is immaterial.

13. SUPPLEMENTARY DISCLOSURES

According to the current regulatory requirements, the Group is only required to disclose the information for the six-month period ended June 30, 2025.

(1) Significant transactions information

A. Loans to others: None.
B. Provision of endorsements and guarantees to others: Refer to table 1.
C. Holding of significant marketable securities at the end of the period (not including subsidiaries, associates and joint ventures): Refer to table 2.
D. Purchases or sales of goods from or to related parties reaching $100 million or 20% of paid-in capital or more: Refer to table 3.
E. Receivables from related parties reaching $100 million or 20% of paid-in capital or more: None.
F. Significant inter-company transactions during the reporting period: Refer to table 4.

(2) Information on investees

Names, locations and other information of investee companies (not including investees in Mainland China): Refer to table 5.

(3) Information on investments in Mainland China

A. Basic information: Refer to table 6.
B. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: Refer to table 1 and table 4.

14. SEGMENT INFORMATION

(1) General information

The management of the Group has identified the operating segments based on how the Company’s Chief Operating Decision-Maker regularly reviews information in order to make decisions. The Chief Operating Decision-Maker manages the Group’s business from geographical and functional perspectives. Geographically, the Group focuses on its sales business in the U.S., Europe and Asia. In addition, the Group categorised its business units into manufacture, sales, research and development and investment management functions, and combines its segments that meet the disclosure threshold as “Others”.

~52~

(2) Segment information

The segment information provided to the Chief Operating Decision-Maker for the reportable segments is as follows:

segments is as follows:
Segment revenue Revenue from internal customers Revenue from external customers `－`API Income －Injection Product Income `－`Technical Service Income `－`Other Operating Income Interest income Depreciation and amortisation Interest expense Income (loss) from segment before income tax Segment assets Other acquisition of non-current assets Segment liabilities Segment revenue Revenue from internal customers Revenue from external customers `－`API Income －Injection Product Income `－`Technical Service Income `－`Other Operating Income Interest income Depreciation and amortisation Interest expense Income from segment before income tax Segment assets Other acquisition of non-current assets Segment liabilities	ScinoPharm SciAnda (Changshu) Taiwan,Ltd. PharmaceuticalsLtd. Others Total 1,420,685 $ 169,483 $ 8,116 $ 1,598,284 $ - 156,817 7,581 164,398 1,420,685 12,666 535 1,433,886 1,247,012 8,038 - 1,255,050 70,965 - - 70,965 77,430 4,628 535 82,593 25,278 - - 25,278 28,849 200 67 29,116 197,476 56,650 457 254,583 3,656 744 - 4,400 171,061 65,110) ( 119 106,070 10,426,129 1,616,792 24,126 12,067,047 73,400 13,119 25 86,544 1,505,617 212,927 1,315 1,719,859 For the six-monthperiod ended June30,2025 For the six-monthperiod ended June30,2024
	ScinoPharm Taiwan,Ltd. 1,514,797 $ 7,061 1,507,736 1,377,009 38,479 57,129 35,119 29,863 185,909 3,658 234,440 10,335,894 86,904 1,500,830	SciAnda (Changshu) PharmaceuticalsLtd. 400,375 $ 263,509 136,866 133,038 - 3,828 - 217 54,429 409 52,709 1,775,301 63,542 155,016	Others 8,216 $ 7,233 983 - - 983 - 94 546 - 1,061 33,719 - 9,884	Total
				1,923,388 $ 277,803 1,645,585 1,510,047 38,479 61,940 35,119 30,174 240,884 4,067 288,210 12,144,914 150,446 1,665,730

~53~

(3) Reconciliation for segment

A. The sales between segments were at arms’ length. The external revenues reported to the Chief Operating Decision-Maker adopt the same measurement basis for revenues in the statement of comprehensive income. The reconciliations of pre-tax income between reportable segments and continuing operations were as follows :

Reportable segments profit before income tax Other segments income before income tax Internal segments transaction elimination ( Profit before income tax	2025 2024 105,951 $ 287,149 $ 119 1,061 1,836) 22,922) ( 104,234 $ 265,288 $ For the six-monthperiods ended June 30,
	2025 105,951 $ 119 1,836) ( 104,234 $

B. The amount of total assets provided to the Chief Operating Decision-Maker adopts the same measurement for assets in the Group’s financial statements. A reconciliation of assets of reportable segments and total assets is as follows:

Assets of reportable segments Assets of other operating segments Internal segment transaction elimination ( Total assets	June 30,2025 12,042,921 $ 24,126 104,539) ( 11,962,508 $	June 30,2024 12,111,195 $ 33,719 149,306) 11,995,608 $

C. The amount of total liabilities provided to the Chief Operating Decision-Maker adopts the same measurement for liabilities in the Group’s financial statements. A reconciliation of liabilities of reportable segments and total liabilities is as follows:

Liabilities of reportable segments Liabilities of other operating segments Internal segment transaction elimination ( Total liabilities	June 30,2025 1,718,544 $ 1,315 25,810) ( 1,694,049 $	June 30,2024 1,655,846 $ 9,884 42,086) 1,623,644 $

~54~

ScinoPharm Taiwan, Ltd. and Subsidiaries

Expressed in thousands of NTD

Provision of endorsements and guarantees to others

For the six-month period ended June 30, 2025

Table 1

Ratio of Party being accumulated endorsed/guaranteed endorsement/ Limit on Maximum Outstanding guarantee Ceiling on Relationship endorsements/ outstanding endorsement/ Amount of amount to net total amount of Provision of Provision of Provision of with the guarantees endorsement/ guarantee endorsements/ asset value of endorsements/ endorsements/g endorsements/g endorsements/g endorser/ provided for a guarantee amount at guarantees the endorser/ guarantees uarantees by uarantees by uarantees to the Endorser/ guarantor single party amount during June 30, Actual amount secured with guarantor provided parent company subsidiary to party in Number guarantor Company name （Note 1）（Note 2） the year 2025 drawn down collateral company （Note 2） to subsidiary parent company Mainland China Footnote 0 ScinoPharm SciAnda 1 $ 10,268,459 $ 180,465 $ - $ - $ - - $ 10,268,459 Y N Y － Taiwan, (Changshu) Ltd. Pharmaceuticals, Ltd.

Note 1: The following code represents the relationship with the Company:

1.A company in which the Company directly and indirectly holds 50% of the voting shares.

Note 2: 1.The limit of total amount of endorsement is 50% of the Company’s net worth, for 100% directly or indirectly owned subsidiaries, the maximum amount is 100% of its net worth.

The limit of total amount of the Group’s endorsement and guarantee is 100% of the Group’s net worth.

2.For any endorsement or guarantee provided by the Company due to business dealings, the amount of endorsement or guarantees shall be limited to the business dealing amount of the most recent year or the current year. The business dealing amount is product purchase or sale amount between the entities, whichever is higher.

Note 3: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the consolidated financial statements (CNY:NTD 1:4.09).

Table 1, Page 1

Table 2

ScinoPharm Taiwan, Ltd. and Subsidiaries

Holding of significant marketable securities at the end of the period (not including subsidiaries, associates and joint ventures)

June 30, 2025

Expressed in thousands of NTD

Securities held by	Marketable securities	Relationship with the securities issuer	General ledger account		As of June 30,2025	As of June 30,2025		Footnote
				Number of shares	Book value	Ownership (%)	Fair value
ScinoPharm Taiwan, Ltd.	Stocks: HANDA PHARMACEUTICALS, INC. Tanvex Biologics, Inc.	The Company is a director of HANDA PHARMACEUTICALS, INC. The Company is a director of Tanvex Biologics, Inc.	Financial assets at fair value through other comprehensive income - non-current Financial assets at fair value through other comprehensive income - non-current	17,000,000 28,800,000	1,250,064 $ 56,535	10.74% 16.84%	1,250,064 $ 56,535	`－` `－`

Table 2, Page 1

Expressed in thousands of NTD

ScinoPharm Taiwan, Ltd. and Subsidiaries

Purchases or sales of goods from or to related parties reaching $100 million or 20% of paid-in capital or more For the six-month period ended June 30, 2025

Table 3

Purchaser/seller	Counterparty	Relationship with the counterparty			Transaction		Differences in t comparedtothird	ransaction terms partytransactions	Notes/accoun	tsreceivable (payable)	Footnote
			Purchases (sales)	Amount	Percentage of total purchases (sales)	Credit term	Unit price	Credit term	Balance	Percentage of total notes/accounts receivable (payable)
ScinoPharm Taiwan, Ltd. SciAnda (Changshu) Pharmaceuticals, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd. ScinoPharm Taiwan, Ltd.	Subsidary The Company	Purchases (Sales)	160,175 $ 160,175) (	37% (97%)	Closes its accounts 90 days from the end of each month Closes its accounts 90 days from the end of each month	- $ -	`－` `－`	21,012) ($ 21,012	(15%) 89%	`－` `－`

Table 3, Page 1

ScinoPharm Taiwan, Ltd. and Subsidiaries

Table 4

- Significant inter company transactions during the reporting period For the six-month period ended June 30, 2025

Expressed in thousands of NTD

Number (Note 2)	Companyname	Counterparty	Relationship (Note 3)		Transactions	Transactions
				General ledger account	Amount	Transaction terms	Percentage of consolidated total operating revenues or total assets (Note 4)
0	ScinoPharm Taiwan, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	1 1	Purchases Accounts Payable	160,175 $ 21,012	Closes its accounts 90 days from the end of each month `－`	11% `－`

Note 1: Significant inter-company transactions during the reporting periods are not disclosed since these were corresponding transactions. Only transactions over NT$10 million are material.

Note 2: The numbers filled in for the transaction company in respect of inter-company transactions are as follows:

(1) Parent company is ‘0’.

(2) The subsidiaries are numbered in order starting from ‘1’.

Note 3: Relationship between transaction company and counterparty is classified into the following three categories:
(1) Parent company to subsidiary.

(2) Subsidiary to parent company.

(3) Subsidiary to subsidiary.

Note 4: Regarding percentage of transaction amount to consolidated total operating revenues or total assets, it is computed based on period-end balance of transaction to consolidated total assets for balance sheet accounts and based on accumulated transaction amount for the period to consolidated total operating revenues for income statement accounts.

Note 5: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the consolidated financial statements (CNY:NTD 1:4.09 ； USD:NTD 1:29.30).

Table 4, Page 1

ScinoPharm Taiwan, Ltd. and Subsidiaries

Expressed in thousands of NTD

Names, locations and other information of investee companies (not including investees in Mainland China)

For the six-month period ended June 30, 2025

Table 5

Investor	Investee	Location	Main business activities	Initial investment amount	Initial investment amount	Shares held as at June 30,2025	Shares held as at June 30,2025	Shares held as at June 30,2025	Net profit of the investee for the six-month period ended June 30,2025	Investment income recognised by the Company for the six-month period ended June 30,2025	Footnote
				Balance as at June 30, 2025	Balance as at December 31, 2024	Number of shares	Ownership (%)	Book value
ScinoPharm Taiwan, Ltd.	SPT International, Ltd. ScinoPharm Singapore Pte Ltd.	Tortola, British Virgin Islands Singapore	Professional investment Professional investment	3,614,585 $ -	3,614,585 $ -	118,524,644 2	100.00 100.00	1,347,718 $ 229	65,027) ($ 10	66,864) ($ 10	Subsidiary Subsidiary

Table 5, Page 1

Expressed in thousands of NTD

Table 6

ScinoPharm Taiwan, Ltd. and Subsidiaries

Information on investments in Mainland China `－` Basic information

For the six-month period ended June 30, 2025

Investee in Mainland China	Main business activities	Paid-in capital	Investment method	Accumulated amount of remittance from Taiwan to Mainland China as of January 1, 2025	Amount remitted from Taiwan to Mainland China/ Amount remitted back to Taiwan for the six-month period ended June 30,2025	Amount remitted from Taiwan to Mainland China/ Amount remitted back to Taiwan for the six-month period ended June 30,2025	Accumulated amount of remittance from Taiwan to Mainland China as of June 30,2025	Net income of investee for the six- month period ended June 30,2025	Ownership held by the Company (direct or indirect)	Investment income recognised by the Company for the six-month period ended June 30, 2025	Book value of investments in Mainland China as of June 30,2025	Accumulated amount of investment income remitted back to Taiwan as of June 30,2025	Footnote
					Remitted to Mainland China	Remitted back to Taiwan
SciAnda (Changshu) Pharmaceuticals, Ltd. SciAnda Shanghai Biochemical Technology, Ltd.	Research, development, and manufacture of API and new drugs, sales of self-produced products, etc. Import, export and sales of API and intermediates, etc.	3,413,450 $ 35,160	`（`Note 1`）` `（`Note 1`）`	3,405,375 $ 35,160	- $ -	- $ -	3,405,375 $ 35,160	65,110) ($ 459	100% 100%	65,110) ($ 459	1,403,866 $ 19,696	- $ -	Subsidary (Note 2) Subsidary (Note 3)

Accumulated amount of Investment amount approved by remittance from Taiwan to the Investment Commission of the Ceiling on investments in Mainland Mainland China Ministry of Economic Affairs China imposed by the Investment Company name as of June 30, 2025 (MOEA) Commission of MOEA (Note 4) ScinoPharm $ 3,476,401 $ 3,476,401 $ 6,161,075 Taiwan, Ltd.

Note 1: Indirect investment in Mainland China through a company set up in a third region, SPT International, Ltd. Note 2: The investment income recognised by the Company for the six-month period ended June 30, 2025 was based on reviewed financial statements of investee companies as of and for the six-month period ended June 30, 2025.

Note 3: The investment income recognised by the Company for the six-month period ended June 30, 2025 was based on unreviewed financial statements of investee companies as of and for the six-month period ended June 30, 2025. Note 4: The ceiling amount is 60% of the higher of net worth or consolidated net worth.

Note 5: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the financial statements (USD:NTD 1:29.30).

Table 6, Page 1

AI assistant

SPT — Interim / Quarterly Report 2025

51922_rns_2025-12-10_84b2fe1a-9d1c-492b-9bbc-2895080d1568.pdf

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES

JUNE 30, 2025 AND 2024 CONSOLIDATED FINANCIAL STATEMENTS AND INDEPENDENT AUDITORS’ REVIEW REPORT

TABLE OF CONTENTS

INDEPENDENT AUDITORS’ REVIEW REPORT TRANSLATED FROM CHINESE

Introduction

Scope of review

Basis for qualified conclusion

Qualified conclusion

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS JUNE 30, 2025, DECEMBER 31, 2024 AND JUNE 30, 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

JUNE 30, 2025, DECEMBER 31, 2024 AND JUNE 30, 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME SIX MONTHS ENDED JUNE 30, 2025 AND 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY SIX MONTHS ENDED JUNE 30, 2025 AND 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS SIX MONTHS ENDED JUNE 30, 2025 AND 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS SIX MONTHS ENDED JUNE 30, 2025 AND 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIODS ENDED JUNE 30, 2025 AND 2024

1. HISTORY AND ORGANISATION

STATEMENTS AND PROCEDURES FOR AUTHORISATION

not yet adopted by the Group

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

(1) Compliance statement

(4) Employee benefits

(5) Income tax

5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

6. DETAILS OF SIGNIFICANT ACCOUNTS

(1) CASH AND CASH EQUIVALENTS

(2) FINANCIAL ASSETS AND LIABILITIES AT FAIR VALUE THROUGH PROFIT OR LOSS

(3) ACCOUNTS RECEIVABLE, NET

(4) INVENTORIES

NON-CURRENT

(6) PROPERTY, PLANT AND EQUIPMENT

(8) IMPAIRMENT OF NON-FINANCIAL ASSETS

(9) SHORT-TERM BORROWINGS

(10) OTHER PAYABLES

(11) PENSIONS

(12) SHARE CAPITAL

(13) CAPITAL RESERVES

(14) SHARE-BASED PAYMENT – EMPLOYEES’ COMPENSATION

B. Details of the share-based payment arrangements are as follows:

(15) RETAINED EARNINGS

(16) OTHER EQUITY ITEMS

(17) OPERATING REVENUE

(18) INTEREST INCOME

(19) OTHER INCOME

(20) OTHER GAINS AND LOSSES

(21) FINANCE COSTS

For the three-month periods ended June 30,

(22) EXPENSES BY NATURE

(23) EMPLOYEE BENEFIT EXPENSES

(24) INCOME TAX

(25) EARNINGS PER SHARE (“EPS”)

(26) SUPPLEMENTAL CASH FLOW INFORMATION

A. Investing activities with partial cash payments:

(27) CHANGES IN LIABILITIES FROM FINANCING ACTIVITIES

7. RELATED PARTY TRANSACTIONS

(1) Parent and ultimate controlling party

(2) Names of related parties and relationship

(3) Significant transactions and balances with related parties

A. Property transactions

For the six-month periods ended June 30,

B. Other expenses

For the three-month periods ended June 30,

(4) Key management compensation

8. PLEDGED ASSETS

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT

COMMITMENTS

10. SIGNIFICANT DISASTER LOSS

11. SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

12. OTHERS

(1) Capital management

(2) Financial instruments

II. Price risk

(b) Credit risk

(c) Liquidity risk

(3) Fair value information

13. SUPPLEMENTARY DISCLOSURES

(1) Significant transactions information

SPT Interim / Quarterly Report 2025

Information on investments in Mainland China `－` Basic information